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Obesity is a prevalent disease in which, when compared to individuals of normal
weight, obese individuals have noted pathophysiological alterations including increased
adiposity and fat mass which may alter toxicokinetics of xenobiotics and therefore alter
their toxicities. However, the effects of obesity and the altered pathophysiology
accompanying this condition on the toxicity of many widely utilized pesticides have not
been established. Organophosphate (OP) pesiticides, including chlorpyrifos (CPS),
have historically been widely used for agricultural purposes. CPS and several other
notable OPs are no longer registered for household use but still used mainly in
agriculture by registered users. CPS is bioactivated to form chlorpyrifos-oxon (CPO) in
liver by cytochrome P450 isozymes. Acute toxicity of CPS exposure is inhibition of
acetylcholinesterase (AChE) in the central and peripheral nervous systems. The other
targets following CPS exposure are the noncholinergic serine hydrolase enzymes:
carboxylesterase (CES), fatty acid amide hydrolase (FAAH), and monoacylglycerol
lipase (MAGL). Therefore the current study was designed to: 1) determine the time and
concentration-dependent effects of CPS on noncholinergic endpoints of OP toxicity

utilizing hepatoma cells under normal and steatotic conditions 2) determine if obese
phenotype altered the toxicity of CPS, including both cholinergic and non-cholinergic
endpoints and 3) determine the effects of high fat diet on CPS bioaccumulation and
detoxication by determining CPS and 3,5,6-trichloro-2-pyridinol (TCP) levels at different
time points. The current in vitro studies determined that CES is more sensitive to CPS
mediated inhibition in normal and steatotic conditions compared to FAAH and MAGL.
The in vivo studies determined that CPS (2 mg/kg) exposure produced a greater
inhibitory effect on hepatic CES and FAAH in obese animals compared to lean animals
which indicates that the obese animals may be at greater risk for CPS mediated
alterations in hepatic lipid metabolism upon chronic exposure. Our toxicokinetic studies
using a higher dose of CPS (25 mg/kg) did not inhibit AChE in CNS and did not alter the
overall CPS levels between normal and obese animals. Peak levels of TCP were
decreased in liver of obese animals at 3 hours and overall hepatic TCP levels were
significantly decreased in obese animals.
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CHAPTER I
INTRODUCTION
1.1

Obesity
According to the Center for Disease Control (CDC), the prevalence of obesity in

the United States is 42.4 percent as of 2017-2018 (Hales et al., 2020). Obesity is a
chronic disease characterized by an increase in visceral fat mass surrounding the
organs and is defined as a body mass index (BMI) greater than or equal to 30 kg/m 2 in
adults (Ogden et al., 2015). The major risk factors for obesity include consumption of
western diets consisting of high fat and high calorie foods and adapting to a sedentary
lifestyle with low physical activity. In addition to these factors, exposure to
environmental pollutants including chemicals or pesticides like organochlorine (OC)
pesticides, polychlorinated biphenyls (PCBs), and organophosphorus (OP) insecticides
may lead to increased susceptibility to developing obesity (Malekirad et al., 2013;
Montgomery et al., 2008; Solomon et al., 2014).
The main clinical feature of obesity is an increase in abdominal fat accompanied
with an increase in body weight. However, a cluster of conditions may occur with
obesity such as high blood pressure, dyslipidemia including alterations in triglyceride
levels or total cholesterol levels, increased low density lipoproteins (LDL), and
decreased levels of high density lipoproteins (HDL) (Fabbrini et al., 2010). Other
metabolic alterations that are commonly found in obese individuals are increased
1

fasting blood glucose levels, increased plasma free fatty acid levels, and alterations in
hepatic lipid metabolism such as increased very low density lipoprotein (VLDL)
synthesis and decreased VLDL secretion (Khaodhiar et al., 1999). Comorbid conditions
often associated with obesity are metabolic syndrome, type 2 diabetes, cardiovascular
disease, and nonalcoholic fatty liver disease (NAFLD) (Kahn et al., 2006; Van Gaal et
al., 2006).

1.2

NAFLD
NAFLD is characterized by liver damage from simple hepatic steatosis with no

use of alcohol or other known liver diseases (Paschos et al., 2009). NAFLD is also
associated with a wide spectrum of disorders including alterations in lipid metabolism,
insulin resistance, and obesity (Fabbrini et al., 2010). Hepatic steatosis is a condition
where the size or weight of the liver is increased by 5 to 10 percent when compared to
the normal liver (Ahmed, 2015). When fat accumulates in the liver it is generally stored
as triglycerides (Gomez-Lechon et al., 2007). Alterations in hepatic lipid metabolism that
can promote steatosis include an increase in the uptake rate of plasma free fatty acids
(which are released from adipose tissue), an increase in hepatic de novo lipogenesis
(DNL), a decrease in hepatic fatty acid oxidation, and a decrease in VLDL secretion
(Dietrich et al., 2014; Fabbrini et al., 2010).
Marked reductions in cytochrome P450 (CYP450) expression and enzymatic
activities of CYP2E and CYP3A isoforms in cultured steatotic human hepatocytes have
been reported which may potentially alter OP metabolism (Donato et al., 2006). In
addition, inflammation of the liver reduced expression of different CYP450 enzyme
2

isoforms including CYP1A2 and CYP3A4, which are also involved in the metabolism of
xenobiotics (Rouimi et al., 2012). The expression and metabolic activities of CYP1A2,
CYP2C19, and CYP3A4 were decreased with increasing severity of NAFLD in humans
and steatotic conditions have been shown to decrease CYP450 enzymatic activity
which may potentially lead to a decrease in CYP450 mediated bioactivation of the
prevalent OP insecticide chlorpyrifos (CPS) (Fisher et al., 2009).

1.3

CPS
OPs are a large class of chemical compounds commercially used as insecticides,

pesticides, and herbicides. There are many chemical types of OPs including
phosphates, phosphorodithioates, phosphonates, and phosphorothionates. CPS is an
organophosphorothioate compound known as O, O-diethyl-O-(3,5,6-trichloro-2pyridinyl)-phosphorothioate (CAS No. 2921-89-2). CPS is the most widely used OP
insecticide in agriculture on a variety of food crops mainly consisting of tree nuts, corn,
and soybeans (Eaton et al., 2008; EPA, 2017). Other non-agricultural settings where
CPS is used include grass turfs, greenhouses, and industrial complexes. In 2000, CPS
was banned from use in household products and restricted to only agricultural purposes
(Stout Ii et al., 2009). The major routes of exposure to CPS in humans are primarily via
dermal, inhalation, and oral. Acute toxic exposures to CPS are mainly due to
occupational accidents or intentional intake. However, lower levels of CPS exposure
can arise from outdoor environments, in homes, occupational areas, and from
consuming contaminated food products (Stout Ii et al., 2009).
OPs, including CPS, are considered lipophilic compounds, and their tissue
3

distribution may vary with lipid content and thus bioaccumulate over time to exert toxic
effects on animals (Bakke et al., 1976; Chambers et al., 1993; Tanvir et al., 2016). It
was previously proposed that the formation of CPS stores in fat and fatty tissues allows
for slower release and gradual bioactivation (Chambers et al., 1993). Based on a
detailed study of the tissue distribution of CPS in rats, the octanol:water partition
coefficients logp values calculated for CPS are brain (33:1), liver (22:1) and adipose
(434:1) (Poulin et al., 1995; Timchalk et al., 2002). In addition, a previous study using
male rats that were orally dosed with C14 labelled CPS (10 mg in 0.5 ml ethanol)
revealed that CPS accumulated in the adipose tissue to a larger extent than the other
tissue compartments (Bakke et al., 1976). Other studies using adult female Wistar rats
that were dosed with CPS (5 mg/kg) for 21 days via oral gavage also indicated that the
highest CPS concentration was detected in the adipose tissue compared to other
tissues (Tanvir et al., 2016).
Rat based studies revealed acute toxicity for lethal doses of CPS (oral dose) to
be 118 mg/kg in male Sherman rats and 163 mg/kg in Dow-Wistar male rats. Female
rats were found to be more sensitive than male rats with an LD50 range reported as 82
mg/kg in female Sherman rats and 135 mg/kg in Dow-Wistar rats (Gaines, 1969;
McCollister et al., 1974). Compared to rats, mice are more susceptible to CPS toxicity.
The acute oral LD50 for CPS in male white mice (strain not specified) was 60 mg/kg (El‐
Sebae et al., 1978). Acute exposure to CPS (12.5 - 100 mg/kg) in adult CD-1 mice
produced cholinergic toxicity, as indicated by increased salivation, lacrimation, urination,
and defecation (SLUD), at doses of ≥25 mg/kg which started 2 hours after treatment
(Cometa et al., 2007). The peak inhibition of brain cholinesterase (ChE) activity (~94%)
4

was observed at 6 hours after dosing with 100 mg/kg CPS and the calculated oral LD 50
for CPS in mice was 60 mg/kg (Cometa et al., 2007).
Regarding age, young animals are more susceptible to acute CPS exposure
based on CPS mediated ChE inhibition which varied up to 10 fold lower depending on
age, dose, and the target tissue (Marty et al., 2012; Pope et al., 1991; Timchalk et al.,
2006; Zheng et al., 2000). Exposure to CPS (1 or 10 mg/kg via oral gavage) in Sprague
Dawley rat pups of different ages (postnatal days (PND) 5, 12, and 17) produced ChE
inhibition of varying degrees in plasma, red blood cells (RBC), and brain. Animals at
PND 5 appeared to be more sensitive than adults at both doses, but PND 12 animals
were only more sensitive at the higher dose (Timchalk et al., 2006). In agreement with
the idea that young animals are more susceptible to acute CPS exposure, another study
that orally exposed Sprague Dawley rat pups at PND 10 to CPS (≤ 1 mg/kg) for 7 days
demonstrated significant inhibition of forebrain acetylcholinesterase (AChE) activity with
CPS (1 mg/kg) (Buntyn et al., 2017).
CPS is considered moderately toxic in humans. An acute dose of CPS (0.5, 1, or
2 mg/kg) via the oral route in fasted human volunteers (males and females) revealed
that CPS (2 mg/kg) significantly inhibited RBC AChE activity after 8 hours with
continued inhibition after 48 hours. However, no clinical signs of cholinergic toxicity
were observed (Kisicki et al., 1999). Another human study with CPS (0.5 mg/kg) in
males indicated significant inhibition of plasma butyrylcholinesterase (BChE) activity
after 12 and 24 hours post dosing with no clinical signs of cholinergic toxicity and no
inhibition of RBC AChE activity (Nolan et al., 1984).

5

1.4

Metabolism and mechanism of toxic action of CPS
The metabolism of phosphorothioate compounds, such as CPS, share a

common mechanism for bioactivation and detoxication. The parent compound can be
bioactivated to toxic metabolites or to nontoxic metabolites that can be readily excreted
in the urine. CPS is bioactivated by CYP450 isozymes via oxidative desulfuration of the
P=S moiety to P=O forming chlorpyrifos-oxon (CPO) (McCollister et al., 1974; Sultatos
et al., 1983). Detoxication of CPS and its potent metabolite CPO can be done by
several enzymes. For example, CPS can be detoxified by CYP450 isoenzymes in a
dearylation reaction to form 3,5,6-trichloro-2-pyridinol (TCP) and diethyl thiophosphate
(DETP). In addition, the A-esterase, paraoxonase-1 (PON-1) and the B-esterase
carboxylesterase (CES) are responsible for the hydrolysis of CPO to the nontoxic
metabolites TCP and diethyl phosphate (DEP) (Chambers et al., 1990; Davis et al.,
2009; Solomon et al., 2014). TCP is the main detoxified metabolite that is routinely
measured in CPS toxicity studies and is used as a biomonitoring metabolite in human
urine samples. CPO can be detoxified by glutathione-S-transferase (GST) in
conjugation with reduced glutathione (GSH) (Cometa et al., 2007). TCP can be
conjugated by glucuronyl transferases and sulfotransferases to form glucuronide and
sulfate conjugates which are readily available to excrete through urine (Testai et al.,
2010).
The major sites for the metabolism of CPS are in the liver and to a lesser extent
in the brain and intestine (Chambers et al., 1989; Forsyth et al., 1989; Sultatos et al.,
1983). The hepatic CYP450 isoforms involved in bioactivation are CYP1A1, CYP2B6,
CYP2C19, and CYP3A4 in humans (Sams et al., 2004). In rats CYP1A1, CYP2B1, and
6

CYP3A2 are involved in bioactivation whereas in mice CYP1a2, CYP2b10, CYP2c29,
and CYP3a11 isoforms are involved in the bioactivation of CPS (Dalvi et al., 2004; Tang
et al., 2001). The major hepatic CYP450 isoforms involved in the dearylation process of
CPS are CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4,
CYP3A5 (Tang et al., 2001).

1.5

Cholinergic targets of CPS toxicity
The primary neurotoxic mechanism of action of OPs is the inhibition of AChE.

AChE is a member of the serine hydrolase family of enzymes. AChE is found at
synapses in both the central and peripheral nervous system at neuronal ganglia and
neuromuscular junctions. CPS is incapable of inhibiting AChE, thus, CPS would need to
be bioactivated to CPO for toxicity to occur (McCollister et al., 1974). CPO’s primary
mechanism of toxic action is inhibition of AChE in humans and animals. The oxon
metabolite irreversibly binds to the esteratic subsite of serine 200 of the active site in the
catalytic triad of AChE which consists of three amino acids serine 200, histidine 440,
and glutamate 327 (Colovic et al., 2013). The main function of AChE (EC 3.1.1.7) is to
rapidly break down the neurotransmitter acetylcholine (ACh) into acetic acid and choline
which terminates ACh neurotransmission (McCollister et al., 1974). ACh is synthesized
in presynaptic neuronal cells and released upon electrical stimulation by nerve impulses
into the synaptic cleft of neuronal ganglia and neuromuscular junctions. Following the
release into the synaptic cleft, ACh binds to and activates muscarinic and nicotinic ACh
receptors which can be located on the postsynaptic neuron, on the presynaptic neuron,
or on the targeted muscle (Fukuto, 1990; Jeger, 2013). AChE inhibition leads to the
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accumulation of ACh and increased activation of muscarinic receptors resulting in
clinical symptoms of SLUD and activation of nicotinic receptors which results in muscle
spasms, tremors, weakness, and eventual paralysis of the diaphragm in the respiratory
system (Eaton et al., 2008; Gaines, 1969).
The other cholinergic target of OP toxicity is the enzyme BChE. BChE (EC
3.1.1.8) is a serine hydrolase synthesized in the liver and mainly found in the plasma
and peripheral tissues such as the liver (Lockridge, 2015). BChE has no known
physiological role but has been shown to be protective against CPO mediated toxicity.
BChE, also called pseudocholinesterase, is an effective molecular scavenger that can
bind to CPO stoichiometrically to its active site (Amitai et al., 1998).
1.6

PON-1
OPs, including CPS, primarily inhibit AChE but they also interact with other

esterases, such as the A-esterase paraoxonases. Paraoxonases are a multigene family
consisting of three enzymes PON-1, PON-2, and PON-3 in humans. PON-1 is the most
widely studied and is present in both humans and rodents. It is synthesized in the liver
and secreted into the serum where it is associated with the HDL particle. The main
mechanism of PON-1 is to provide protection against disease conditions like
inflammation and atherosclerosis. PON-1 and other paraoxonases have the ability to
hydrolyze peroxides and lactones to protect against oxidation of HDL and LDL particles
(Costa et al., 2005). PON-1 also protects against toxicity mediated by OP oxon
metabolites including paraoxon, diazoxon, and CPO (Costa et al., 1999). PON-1 also
can hydrolyze non phosphorus aryl ester compounds including phenylacetate by
arylesterase activity (Gan et al., 1991). Human PON-1 has two common single
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nucleotide polymorphisms (SNPs) which are Q192R and L55M. The catalytic
efficiencies of PON-1 polymorphisms are different with different substrates including
paraoxon and CPO (Mackness et al., 1998). The PON-1 (192R) allele of polymorphic
PON-1 Q192R enzyme was shown to be more efficient in the hydrolysis of CPO than
the PON-1 (192Q) allele (Cole et al., 2005). Also, PON-/- knockout mouse studies have
demonstrated that the absence of PON-1 activity increased the sensitivity of CPO
mediated toxicity. Administration of purified rabbit PON-1 protects from CPO mediated
toxicity by decreasing the inhibition of AChE (Li et al., 1993).

1.7

CES
CESs are key enzymes of the serine hydrolase family that are involved in the

hydrolysis of endogenous substrates, drugs, and environmental chemicals that contain
ester, amide, or thioester bonds. CES’s main role in xenobiotic metabolism, like
metabolizing OP oxon metabolites such as CPO, is to act as a molecular scavenger that
binds stoichiometrically to OP oxon metabolites to decrease the concentrations of free
oxon in the blood (Casida et al., 2005; Chambers et al., 1993). The human CES
isoforms are mainly expressed in metabolic organs including the liver and adipose
tissues. The major CES isoforms expressed in these tissues are CES1, CES2, and
CES3 (Holmes et al., 2010). The CES in rodents are expressed mainly in the liver,
adipose, and plasma (Ross et al., 2007). Human CES1 is annotated as Ces1g in mice
and Ces1/esterase-x (ES-x) in rats, Ces1d in mice annotated as Ces3/triacylglycerol
hydrolase (TGH) in rats (Lian et al., 2018). CES1 is mainly involved in the hydrolysis of
endogenous compounds, such as triacylglycerol (TAG), and cholesteryl esters (CE), but
9

it is also involved in the breakdown of 2-arachidonoylglycerol (2-AG), a major
endocannabinoid (Ross et al., 2007; Szafran et al., 2015). In vivo studies reported that
both Ces1d/Ces3/TGH and Ces1g/Ces1/Es-x play a regulatory role in the liver by
providing and mobilizing endogenous lipid substrates to the apolipoprotein B (apo B) for
the assembly of VLDL particles and its secretion (Lehner et al., 1999). Studies with
Ces1/Es-x knockout mice also showed an increase in the partitioning of fatty acids in
association with hepatic lipogenesis resulting in over secretion of VLDL which leads to
increased hepatic fat deposition contributing to metabolic disorders including fatty liver
and obesity (Quiroga et al., 2012).

1.8

Endocannabinoid (ECB) system
The ECB system is also a potential target of OP toxicity including CPS (Casida et

al., 2005). The ECB system consists of two cannabinoid (CB) receptors, CB1 and CB2.
The CB receptors are G-protein coupled receptors (GPCR) expressed mainly in the
brain, but they are also found in the peripheral tissues such as adipose and the liver
tissues (El Manira et al., 2010). The ECB system consists of two best studied ECBs,
anandamide (AEA) and 2-AG which act on both CB receptors. The ECB's are lipid
mediators synthesized on demand from membrane derived phospholipids. The ECB
system also consists of two enzymes of the serine hydrolase family which are fatty acid
amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). AEA is specifically
degraded by FAAH to arachidonic acid (AA) and 2-AG is degraded to AA mainly by
MAGL. However, FAAH and CES are also involved in the degradation of 2-AG to a
lesser extent (Quistad et al., 2006; Quistad et al., 2001). The ECB system in humans
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and rodents is involved in physiological functions including neuroprotection,
inflammation, pain modulation, appetite control, and peripheral lipid metabolism (Di
Marzo, 2008). The CB2 receptors are mainly expressed in the peripheral nervous
system and immune cells where activation of CB2 receptors acts as a protective
mechanism to reduce inflammation and regulate the modulation of pain (De Petrocellis
et al., 2009). The CB1 receptors are highly expressed in the brain and liver, CB1
receptors are mainly responsible for mediating hepatic lipid metabolism by stimulating
the synthesis of sterol regulatory element binding protein (SREBP-1c) and its
associated lipogenic genes including acetyl-CoA carboxylase-1 (ACC-1) and fatty acid
synthase (FAS). Inhibition of ECB metabolizing enzymes (FAAH and MAGL) leads to an
increase in the levels of AEA and 2-AG which in turn increase the activation of CB1.
Thus decreased degradation of AEA or 2-AG may increase in DNL via the CB1 receptor
activation and lead to dyslipidemia which is a key pathophysiological alteration in
obesity and hepatic steatosis (Carr et al., 2011; Casida et al., 2005; De Gottardi et al.,
2010; Di Marzo, 2008; Osei-Hyiaman et al., 2008).

1.9

CPS exposures and metabolic disorders
Epidemiological studies have shown that exposure to environmental chemicals

like heavy metals, persistent organic pollutants, and pesticides including OPs is linked
with an increase in the incidence of metabolic diseases including obesity, type 2
diabetes, and NAFLD (Meggs et al., 2007; Montgomery et al., 2008; Mustieles et al.,
2020). The underlying mechanisms that govern the OP exposure effect on lipid
metabolism that may lead to metabolic diseases including obesity and NAFLD are not
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fully elucidated. Previous studies from our lab using a hepatocyte model demonstrated
exposure to a range of CPS concentrations produced an increase in neutral lipid
accumulation and have also shown an increase in DNL with a decrease in VLDL
secretion. These alterations of hepatic lipid metabolism following CPS exposure may
lead to hepatic steatosis (Howell et al., 2016). In vivo studies using subcutaneous
injection of CPS (5 mg/kg/day) for 4 months in Long Evans rats caused a significant
increase in body weights associated with an increase in fat mass of adipose tissue
(Meggs et al., 2007). Subcutaneous administration of CPS (1 mg/kg) during PND (1-4)
in Sprague Dawley rats produced an increase in plasma total cholesterol levels and
triglyceride levels in adulthood (Slotkin et al., 2005). Also, acute subcutaneous
administration of CPS (50 mg/kg) in Wistar rats has been shown to induce
hyperlipidemia and hyperglycemia with alterations in cholesterol and triglyceride levels
(Acker et al., 2012).

1.10

Research summary
The current research is designed based on the hypothesis that CPS toxicity will

be increased in obesity or steatosis due to the altered physiological process including
lipid accumulation. The liver a major organ involved in lipid metabolism and detoxication
of xenobiotics (McCollister et al., 1974). CPS is also bioactivated to CPO predominately
in the liver and CPO has the ability to inhibit serine hydrolases including CES, FAAH,
and MAGL (Casida et al., 2005). Based on previous studies from our lab, CPS exposure
can increase intracellular neutral lipid accumulation and hepatic lipogenesis in vitro
(Howell et al., 2016). This effect may be due to OP induced inhibition of noncholinergic
12

targets mainly consisting of CES, FAAH, and MAGL which are involved in different
pathophysiological processes including xenobiotic metabolism and lipid metabolism in
the liver.
Chapter 2 focuses on in vitro studies in which we determined the effects of
exposing rat hepatocytes to CPS. This research specifically determined the selective
potency of CPS exposures on the inhibition of the noncholinergic targets of OP toxicity
and evaluating inhibitory concentration 50 (IC50) values. Two fatty acids (FAs), oleic acid
(OA), and palmitic acid (PA), which are highly available in western diets are utilized to
induce steatosis. It is hypothesized that the steatotic conditions will increase the CPS
mediated inhibition of these serine hydrolase targets.
In chapter 3 we determined the effects of high-fat diet induced obesity on acute
CPS (2 mg/kg) toxicity by examining both cholinergic (AChE) and noncholinergic (CES,
FAAH, MAGL) endpoints. Obesity is a condition characterized by alterations in
pathophysiological processes including an increase in abdominal fat mass and
alterations in lipid metabolism (Singla et al., 2010). Obesity was shown to be positively
correlated with OP toxicity in a study where patients exposed to lipophilic OP
compounds needed longer recovery times when compared to normal patients (Lee et
al., 2014). The focus of chapter 3 of this current study is based on the hypothesis that
high-fat diet induced obesity increases the severity of CPS toxicity on cholinergic and
noncholinergic endpoints.
CPS is a lipophilic compound and it may accumulate in fat and leach out slowly
over the prolonged period (Chambers et al., 1993). Therefore, obesity may interfere with
CPS bioavailability and metabolism and may affect CPS toxicity. Thus, in chapter 4 we
13

used CPS (25 mg/kg) to perform a toxicokinetic study in both standard chow and high
fat fed mice to determine if obesity altered the appearance and/or disappearance of
CPS and TCP in the liver and plasma. The higher dose of CPS was utilized to recover
the parent compound CPS in plasma and the liver. This chapter’s focus was based on
the hypothesis that high fat diet induced obesity in mice will increase the
bioaccumulation of CPS, decrease the bioactivation of CPS to CPO, and increase
detoxication of CPS/CPO to TCP.

14

References
Acker, C. I., & Nogueira, C. W. (2012). Chlorpyrifos acute exposure induces
hyperglycemia and hyperlipidemia in rats. Chemosphere, 89(5), 602-608.
doi:10.1016/j.chemosphere.2012.05.059
Ahmed, M. (2015). Non-alcoholic fatty liver disease in 2015. World J Hepatol, 7(11),
1450-1459. doi:10.4254/wjh.v7.i11.1450
Amitai, G., Moorad, D., Adani, R., & Doctor, B. (1998). Inhibition of acetylcholinesterase
and butyrylcholinesterase by chlorpyrifos-oxon. Biochem Pharmacol, 56(3), 293299.
Bakke, J. E., Feil, V. J., & Price, C. E. (1976). Rat urinary metabolites from O,O-diethylO-(3,5,6-trichloro-2-pyridyl) phosphorothioate. J Environ Sci Health B, 11(3), 225230. doi:10.1080/03601237609372038
Buntyn, R. W., Alugubelly, N., Hybart, R. L., Mohammed, A. N., Nail, C. A., Parker, G.
C., Carr, R. L. (2017). Inhibition of endocannabinoid-metabolizing enzymes in
peripheral tissues following developmental chlorpyrifos exposure in rats.
International journal of toxicology, 36(5), 395-402.
Carr, R. L., Borazjani, A., & Ross, M. K. (2011). Effect of developmental chlorpyrifos
exposure, on endocannabinoid metabolizing enzymes, in the brain of juvenile
rats. Toxicol Sci, 122(1), 112-120. doi:10.1093/toxsci/kfr081
Casida, J. E., & Quistad, G. B. (2005). Serine hydrolase targets of organophosphorus
toxicants. Chem Biol Interact, 157-158, 277-283. doi:10.1016/j.cbi.2005.10.036
Chambers, H., Brown, B., & Chambers, J. E. (1990). Noncatalytic detoxication of six
organophosphorus compounds by rat liver homogenates. Pesticide Biochemistry
and Physiology, 36(3), 308-315.
Chambers, J. E., & Carr, R. L. (1993). Inhibition patterns of brain acetylcholinesterase
and hepatic and plasma aliesterases following exposures to three
phosphorothionate insecticides and their oxons in rats. Fundam Appl Toxicol,
21(1), 111-119. doi:10.1006/faat.1993.1079
Chambers, J. E., & Chambers, H. W. (1989). Oxidative desulfuration of chlorpyrifos,
chlorpyrifos-methyl, and leptophos by rat brain and liver. J Biochem Toxicol, 4(3),
201-203. doi:10.1002/jbt.2570040310
Cole, T. B., Walter, B. J., Shih, D. M., Tward, A. D., Lusis, A. J., Timchalk, C., Furlong,
C. E. (2005). Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse
model of the human paraoxonase (PON1) Q192R polymorphism.
Pharmacogenetics and genomics, 15(8), 589-598.
15

Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M.
(2013). Acetylcholinesterase inhibitors: pharmacology and toxicology. Current
neuropharmacology, 11(3), 315-335.
Cometa, M. F., Buratti, F. M., Fortuna, S., Lorenzini, P., Volpe, M. T., Parisi, L.,
Meneguz, A. (2007). Cholinesterase inhibition and alterations of hepatic
metabolism by oral acute and repeated chlorpyrifos administration to mice.
Toxicology, 234(1-2), 90-102. doi:10.1016/j.tox.2007.02.008
Costa, L. G., Cole, T. B., Vitalone, A., & Furlong, C. E. (2005). Measurement of
paraoxonase (PON1) status as a potential biomarker of susceptibility to
organophosphate toxicity. Clin Chim Acta, 352(1-2), 37-47.
doi:10.1016/j.cccn.2004.09.019
Costa, L. G., Li, W. F., Richter, R. J., Shih, D. M., Lusis, A., & Furlong, C. E. (1999). The
role of paraoxonase (PON1) in the detoxication of organophosphates and its
human polymorphism. Chem Biol Interact, 119-120, 429-438. doi:10.1016/s00092797(99)00055-1
Dalvi, R. R., Dalvi, P. S., & Lane, C. (2004). Cytochrome P450-mediated activation and
toxicity of chlorpyrifos in male and female rats. Veterinary and human toxicology,
46(6), 297-299.
Davis, K. A., Crow, J. A., Chambers, H. W., Meek, E. C., & Chambers, J. E. (2009).
Racial differences in paraoxonase-1 (PON1): a factor in the health of
southerners? Environ Health Perspect, 117(8), 1226-1231.
doi:10.1289/ehp.0900569
De Gottardi, A., Spahr, L., Ravier‐Dall'Antonia, F., & Hadengue, A. (2010). Cannabinoid
receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. Liver
international, 30(10), 1482-1489.
De Petrocellis, L., & Di Marzo, V. (2009). An introduction to the endocannabinoid
system: from the early to the latest concepts. Best Practice & Research Clinical
Endocrinology & Metabolism, 23(1), 1-15.
Di Marzo, V. (2008). The endocannabinoid system in obesity and type 2 diabetes.
Diabetologia, 51(8), 1356-1367. doi:10.1007/s00125-008-1048-2
Dietrich, P., & Hellerbrand, C. (2014). Non-alcoholic fatty liver disease, obesity and the
metabolic syndrome. Best Pract Res Clin Gastroenterol, 28(4), 637-653.
doi:10.1016/j.bpg.2014.07.008
Donato, M. T., Lahoz, A., Jimenez, N., Perez, G., Serralta, A., Mir, J., Gomez-Lechon,
M. J. (2006). Potential impact of steatosis on cytochrome P450 enzymes of
human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos, 34(9),
1556-1562. doi:10.1124/dmd.106.009670
16

Eaton, D. L., Daroff, R. B., Autrup, H., Bridges, J., Buffler, P., Costa, L. G., Nadel, L.
(2008). Review of the toxicology of chlorpyrifos with an emphasis on human
exposure and neurodevelopment. Critical reviews in toxicology, 38(sup2), 1-125.
El‐Sebae, A., Ahmed, N. S., & Soliman, S. (1978). Effect of pre‐exposure on acute
toxicity of organophosphorus insecticides to white mice. Journal of Environmental
Science & Health Part B, 13(1), 11-24.
El Manira, A., & Kyriakatos, A. (2010). The role of endocannabinoid signaling in motor
control. Physiology, 25(4), 230-238.
EPA, U. (2017). Revised Human Health Risk Assessment on Chlorpyrifos.
Fabbrini, E., Sullivan, S., & Klein, S. (2010). Obesity and nonalcoholic fatty liver
disease: biochemical, metabolic, and clinical implications. Hepatology, 51(2),
679-689. doi:10.1002/hep.23280
Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P.,
Ferguson, S. S., & Cherrington, N. J. (2009). Hepatic cytochrome P450 enzyme
alterations in humans with progressive stages of nonalcoholic fatty liver disease.
Drug Metabolism and Disposition, 37(10), 2087-2094.
Forsyth, C. S., & Chambers, J. E. (1989). Activation and degradation of the
phosphorothionate insecticides parathion and EPN by rat brain. Biochem
Pharmacol, 38(10), 1597-1603. doi:10.1016/0006-2952(89)90307-9
Fukuto, T. R. (1990). Mechanism of action of organophosphorus and carbamate
insecticides. Environ Health Perspect, 87, 245-254.
Gaines, T. B. (1969). Acute toxicity of pesticides. Toxicol Appl Pharmacol, 14(3), 515534.
Gan, K. N., Smolen, A., Eckerson, H. W., & La Du, B. N. (1991). Purification of human
serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both
activities. Drug Metab Dispos, 19(1), 100-106.
Gomez-Lechon, M. J., Donato, M. T., Martínez-Romero, A., Jiménez, N., Castell, J. V.,
& O’Connor, J.-E. (2007). A human hepatocellular in vitro model to investigate
steatosis. Chem Biol Interact, 165(2), 106-116.
Hales, C. M., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2020). Prevalence of obesity
and severe obesity among adults: United States, 2017–2018.
Holmes, R. S., Wright, M. W., Laulederkind, S. J., Cox, L. A., Hosokawa, M., Imai, T., . .
. Maltais, L. J. (2010). Recommended nomenclature for five mammalian
carboxylesterase gene families: human, mouse, and rat genes and proteins.
Mamm Genome, 21(9-10), 427-441. doi:10.1007/s00335-010-9284-4
17

Howell, G. E., 3rd, Mulligan, C., Young, D., & Kondakala, S. (2016). Exposure to
chlorpyrifos increases neutral lipid accumulation with accompanying increased
de novo lipogenesis and decreased triglyceride secretion in McArdle-RH7777
hepatoma cells. Toxicol In Vitro, 32, 181-189. doi:10.1016/j.tiv.2016.01.002
Jeger, R. V. (2013). Mens sana in corpore sano revisited. Eur Heart J, 34(33), 25802581. doi:10.1093/eurheartj/eht244
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity to
insulin resistance and type 2 diabetes. Nature, 444(7121), 840-846.
doi:10.1038/nature05482
Khaodhiar, L., McCowen, K. C., & Blackburn, G. L. (1999). Obesity and its comorbid
conditions. Clinical cornerstone, 2(3), 17-31.
Kisicki, J., Seip, C., & Combs, M. (1999). A rising dose toxicology study to determine
the no-observable-effect-levels (NOEL) for erythrocyte acetylcholinesterase
(AchE) inhibition and cholinergic signs and symptoms of chlorpyrifos at three
dose levels. Unpublished report from MDS Harris. MRID(44811002).
Lee, D. H., Jung, K. Y., Choi, Y. H., & Cheon, Y. J. (2014). Body mass index as a
prognostic factor in organophosphate-poisoned patients. Am J Emerg Med,
32(7), 693-696. doi:10.1016/j.ajem.2014.04.030
Lehner, R., Cui, Z., & Vance, D. E. (1999). Subcellullar localization, developmental
expression and characterization of a liver triacylglycerol hydrolase. Biochem J,
338 ( Pt 3)(Pt 3), 761-768.
Li, W. F., Costa, L. G., & Furlong, C. E. (1993). Serum paraoxonase status: a major
factor in determining resistance to organophosphates. Journal of Toxicology and
Environmental Health, Part A Current Issues, 40(2-3), 337-346.
Lian, J., Nelson, R., & Lehner, R. (2018). Carboxylesterases in lipid metabolism: from
mouse to human. Protein & cell, 9(2), 178-195.
Lockridge, O. (2015). Review of human butyrylcholinesterase structure, function,
genetic variants, history of use in the clinic, and potential therapeutic uses.
Pharmacol Ther, 148, 34-46. doi:10.1016/j.pharmthera.2014.11.011
Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., & Durrington, P. N. (1998). Effect
of the human serum paraoxonase 55 and 192 genetic polymorphisms on the
protection by high density lipoprotein against low density lipoprotein oxidative
modification. FEBS Lett, 423(1), 57-60. doi:10.1016/s0014-5793(98)00064-7
Malekirad, A. A., Faghih, M., Mirabdollahi, M., Kiani, M., Fathi, A., & Abdollahi, M.
(2013). Neurocognitive, mental health, and glucose disorders in farmers exposed
to organophosphorus pesticides. Arh Hig Rada Toksikol, 64(1), 1-8.
18

Marty, M. S., Andrus, A. K., Bell, M. P., Passage, J. K., Perala, A. W., Brzak, K. A.,
Juberg, D. R. (2012). Cholinesterase inhibition and toxicokinetics in immature
and adult rats after acute or repeated exposures to chlorpyrifos or chlorpyrifosoxon. Regul Toxicol Pharmacol, 63(2), 209-224. doi:10.1016/j.yrtph.2012.03.015
McCollister, S. B., Kociba, R., Humiston, C., McCollister, D., & Gehring, P. (1974).
Studies of the acute and long-term oral toxicity of chlorpyrifos (O, O-diethyl-O-(3,
5, 6-trichloro-2-pyridyl) phosphorothioate). Food and cosmetics toxicology, 12(1),
45-61.
Meggs, W. J., & Brewer, K. L. (2007). Weight gain associated with chronic exposure to
chlorpyrifos in rats. J Med Toxicol, 3(3), 89-93. doi:10.1007/bf03160916
Montgomery, M. P., Kamel, F., Saldana, T. M., Alavanja, M. C., & Sandler, D. P. (2008).
Incident diabetes and pesticide exposure among licensed pesticide applicators:
Agricultural Health Study, 1993-2003. Am J Epidemiol, 167(10), 1235-1246.
doi:10.1093/aje/kwn028
Mustieles, V., & Arrebola, J. P. (2020). How polluted is your fat? What the study of
adipose tissue can contribute to environmental epidemiology. J Epidemiol
Community Health, 74(5), 401-407. doi:10.1136/jech-2019-213181
Nolan, R., Rick, D., Freshour, N., & Saunders, J. (1984). Chlorpyrifos: pharmacokinetics
in human volunteers. Toxicol Appl Pharmacol, 73(1), 8-15.
Ogden, C. L., Carroll, M. D., Fryar, C. D., & Flegal, K. M. (2015). Prevalence of Obesity
Among Adults and Youth: United States, 2011-2014. NCHS Data Brief(219), 1-8.
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W. I.,
Kunos, G. (2008). Hepatic CB1 receptor is required for development of dietinduced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin
Invest, 118(9), 3160-3169. doi:10.1172/jci34827
Paschos, P., & Paletas, K. (2009). Non alcoholic fatty liver disease and metabolic
syndrome. Hippokratia, 13(1), 9-19.
Pope, C. N., Chakraborti, T. K., Chapman, M. L., Farrar, J. D., & Arthun, D. (1991).
Comparison of in vivo cholinesterase inhibition in neonatal and adult rats by three
organophosphorothioate insecticides. Toxicology, 68(1), 51-61.
doi:10.1016/0300-483x(91)90061-5
Poulin, P., & Krishnan, K. (1995). An algorithm for predicting tissue: blood partition
coefficients of organic chemicals from n‐octanol: water partition coefficient data.
Journal of Toxicology and Environmental Health, Part A Current Issues, 46(1),
117-129.

19

Quiroga, A. D., Li, L., Trotzmuller, M., Nelson, R., Proctor, S. D., Kofeler, H., & Lehner,
R. (2012). Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic
steatosis, and hyperlipidemia. Hepatology, 56(6), 2188-2198.
doi:10.1002/hep.25961
Quistad, G. B., Klintenberg, R., Caboni, P., Liang, S. N., & Casida, J. E. (2006).
Monoacylglycerol lipase inhibition by organophosphorus compounds leads to
elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice.
Toxicol Appl Pharmacol, 211(1), 78-83. doi:10.1016/j.taap.2005.10.007
Quistad, G. B., Sparks, S. E., & Casida, J. E. (2001). Fatty acid amide hydrolase
inhibition by neurotoxic organophosphorus pesticides. Toxicol Appl Pharmacol,
173(1), 48-55. doi:10.1006/taap.2001.9175
Ross, M. K., & Borazjani, A. (2007). Enzymatic activity of human carboxylesterases.
Curr Protoc Toxicol, Chapter 4, Unit 4.24. doi:10.1002/0471140856.tx0424s33
Rouimi, P., Zucchini-Pascal, N., Dupont, G., Razpotnik, A., Fouche, E., De Sousa, G., &
Rahmani, R. (2012). Impacts of low doses of pesticide mixtures on liver cell
defence systems. Toxicol In Vitro, 26(5), 718-726. doi:10.1016/j.tiv.2012.03.015
Sams, C., Cocker, J., & Lennard, M. (2004). Biotransformation of chlorpyrifos and
diazinon by human liver microsomes and recombinant human cytochrome P450s
(CYP). Xenobiotica, 34(10), 861-873.
Singla, P., Bardoloi, A., & Parkash, A. A. (2010). Metabolic effects of obesity: a review.
World journal of diabetes, 1(3), 76.
Slotkin, T. A., Brown, K. K., & Seidler, F. J. (2005). Developmental exposure of rats to
chlorpyrifos elicits sex-selective hyperlipidemia and hyperinsulinemia in
adulthood. Environ Health Perspect, 113(10), 1291-1294. doi:10.1289/ehp.8133
Solomon, K. R., Williams, W. M., Mackay, D., Purdy, J., Giddings, J. M., & Giesy, J. P.
(2014). Properties and uses of chlorpyrifos in the United States Ecological Risk
Assessment for Chlorpyrifos in Terrestrial and Aquatic Systems in the United
States (pp. 13-34): Springer, Cham.
Stout Ii, D. M., Bradham, K. D., Egeghy, P. P., Jones, P. A., Croghan, C. W., Ashley, P.
A., Cox, D. C. (2009). American Healthy Homes Survey: A National Study of
Residential Pesticides Measured from Floor Wipes. Environmental Science &
Technology, 43(12), 4294-4300. doi:10.1021/es8030243
Sultatos, L. G., & Murphy, S. D. (1983). Hepatic microsomal detoxification of the
organophosphates paraoxon and chlorpyrifos oxon in the mouse. Drug Metab
Dispos, 11(3), 232-238.

20

Szafran, B., Borazjani, A., Lee, J. H., Ross, M. K., & Kaplan, B. L. (2015).
Lipopolysaccharide suppresses carboxylesterase 2g activity and 2arachidonoylglycerol hydrolysis: A possible mechanism to regulate inflammation.
Prostaglandins Other Lipid Mediat, 121(Pt B), 199-206.
doi:10.1016/j.prostaglandins.2015.09.005
Tang, J., Cao, Y., Rose, R. L., Brimfield, A. A., Dai, D., Goldstein, J. A., & Hodgson, E.
(2001). Metabolism of Chlorpyrifos by Human Cytochrome P450 Isoforms and
Human, Mouse, and Rat Liver Microsomes. Drug Metabolism and Disposition,
29(9), 1201-1204.
Tanvir, E. M., Afroz, R., Chowdhury, M., Gan, S. H., Karim, N., Islam, M. N., & Khalil, M.
I. (2016). A model of chlorpyrifos distribution and its biochemical effects on the
liver and kidneys of rats. Hum Exp Toxicol, 35(9), 991-1004.
doi:10.1177/0960327115614384
Testai, E., Buratti, F. M., & Di Consiglio, E. (2010). Chlorpyrifos Hayes' Handbook of
Pesticide Toxicology (pp. 1505-1526): Elsevier.
Timchalk, C., Nolan, R., Mendrala, A., Dittenber, D., Brzak, K., & Mattsson, J. (2002). A
physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model
for the organophosphate insecticide chlorpyrifos in rats and humans.
Toxicological Sciences, 66(1), 34-53.
Timchalk, C., Poet, T. S., & Kousba, A. A. (2006). Age-dependent pharmacokinetic and
pharmacodynamic response in preweanling rats following oral exposure to the
organophosphorus insecticide chlorpyrifos. Toxicology, 220(1), 13-25.
doi:10.1016/j.tox.2005.11.011
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006). Mechanisms linking obesity
with cardiovascular disease. Nature, 444(7121), 875-880.
doi:10.1038/nature05487
Zheng, Q., Olivier, K., Won, Y. K., & Pope, C. N. (2000). Comparative cholinergic
neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. Toxicol
Sci, 55(1), 124-132.

21

CHAPTER II
DETERMINE THE EFFECTS OF CHLORPYRIFOS (CPS) EXPOSURE ON
NONCHOLINERGIC ENDPOINTS OF ORGANOPHOSPHATE (OP)
TOXICITYIN MCARDLE-RH7777 (MCA) CELLS AND PRIMARY
HEPATOCYTES UNDER NORMAL AND HIGH FAT
CONDITIONS.
2.1

Introduction
The prevalence of obesity in the United States has risen alarmingly in children

and adults. In obese individuals, there are altered pathophysiological conditions
including increased visceral fat mass, increased adiposity, and altered cholesterol levels
compared to normal individuals (Ogden et al., 2015). Obesity is often linked to other
chronic disease conditions including type 2 diabetes and non-alcoholic fatty liver
disease (NAFLD). NAFLD is mainly characterized by hepatic steatosis, which is due to
a substantial increase in hepatic triglyceride content. Fatty liver is considered to be the
hepatic component of the metabolic syndrome. Also, fatty liver has been indicated as a
precursor of a more severe liver disease, nonalcoholic steatohepatitis, which can then
progress to cirrhosis, and ultimately necessitate liver transplantation. While the etiology
of NAFLD has not been fully elucidated, it has been established that elevated serum
free fatty acids leading to increased hepatic de novo lipogenesis (DNL) play a major role
in the formation of hepatic steatosis (Bacon et al., 1994; Fabbrini et al., 2010).
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Several recent studies have shown that exposure to OP pesticides, including
chlorpyrifos CPS, leads to the metabolic abnormalities accompanying obesity and
NAFLD (Howell et al., 2016; Slotkin et al., 2005). CPS is an OP insecticide that has
extensive applications in commercial and agriculture purposes. In 2000, CPS was
banned from household usage (Stout Ii et al., 2009). To exert its toxicity, CPS has to be
bioactivated by desulfuration to its active oxon form, chlorpyrifos-oxon (CPO), in the
liver by cytochrome P450 (CYP450) isozymes (Chambers et al., 1989). CPO is
considered to be primarily neurotoxic due to its ability to inhibit acetylcholinesterase
(AChE) in the central nervous system. However, CPO can also produce effects in the
periphery, and possibly the central nervous system, by inhibiting other serine hydrolase
enzymes producing potential noncholinergic endpoints of OP toxicity mainly by targeting
monoacylglycerol lipase (MAGL), fatty acid amide hydrolase (FAAH) and
carboxylesterases (CES) (Casida et al., 2005; Quistad et al., 2006; Quistad et al., 2001;
Ross et al., 2007).
CES belong to the serine hydrolase superfamily and are capable of detoxication
by catalyzing the hydrolysis of the OP oxon metabolites and other xenobiotics. CES are
also involved in the hydrolysis of 2-arachidonyl glycerol (2-AG) and hepatic
triacylglycerol metabolism (Ko et al., 2009; Szafran et al., 2015). MAGL and FAAH
belong to the endocannabinoid (ECB) system. The ECB system consists of G-protein
coupled cannabinoid receptors, CB1 and CB2 as well as two major ECBs, such as
anandamide (AEA) and 2-AG. AEA and 2-AG are lipid mediators produced on demand
in tissues such as the brain and liver (Osei-Hyiaman et al., 2005). The CB1 receptors
are present in the peripheral organs, such as the liver, and in the central nervous
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system whereas CB2 receptors are mainly present in immune cells (Di Marzo, 2008).
AEA and 2-AG can act as agonists of both CB1 and CB2 receptors. Activation of
hepatic CB1 receptors results in increased DNL through the induction of the lipogenic
transcription factor sterol regulatory element binding protein–1c (SREBP-1c) and its
target enzymes acetyl coenzyme A carboxylase-1 (ACC-1), fatty acid synthase (FAS)
and reduced fatty acid β-oxidation (Di Marzo, 2008; Osei-Hyiaman et al., 2005). The two
main metabolizing enzymes of the ECB system MAGL and FAAH hydrolyze 2-AG and
AEA, respectively, to form AA. AEA is however specifically hydrolyzed by only FAAH
but 2-AG though primarily hydrolyzed by MAGL, can also be hydrolyzed by FAAH and
CES (Carr et al., 2013; Casida et al., 2005).
Inflammation is a factor often associated with different disease states such as
obesity, diabetes, and hepatic steatosis (Brill et al., 2012). The expression of different
CYP enzyme isoforms including CYP1A2 and CYP3A4, which are also involved in
xenobiotic metabolism, has been shown to be reduced in steatohepatitis (Rouimi et al.,
2012). Therefore, the present study was designed to determine the effects of CPS on
noncholinergic endpoints of OP toxicity in normal and fatty acid induced steatotic
conditions. Several studies have determined exposure to OP pesticides, including CPS,
produces an effect on noncholinergic endpoints by inhibiting the enzymatic activities of
targeted serine hydrolases including CES, FAAH, and MAGL (Casida et al., 2005;
Chambers et al., 1993; Quistad et al., 2006; Quistad et al., 2001; Ross et al., 2007).
Quistad et al. (2006) tested the in vitro sensitivity and potency of CPO for FAAH and
MAGL in the mouse brain and liver homogenates and determined the IC50 values as 40
– 56 nM and 30 nM, respectively (Quistad et al., 2006; Quistad et al., 2001). In vivo
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studies in male albino Swiss Webster mice treated intraperitoneally with CPS (30
mg/kg) revealed that after 4 hours, CPS exposure potently inhibited MAGL (40%) and
FAAH (61%) activities in the brain (Quistad et al., 2006). Oral exposure to CPS (0.5
mg/kg – 1 mg/kg) in Sprague Dawley rat pups dosed from PND 10 – 16 days revealed
hepatic FAAH activity was significantly inhibited by CPS (0.5 mg/kg) and decreased
MAGL activity was observed with 1 mg/kg CPS dosage group (Buntyn et al., 2017).
Previous studies assessed the potency of CPO inhibition of recombinant human CES1
and CES2 isoforms and the IC50 values were determined as 0.15 nM and 0.33 nM for
CES1 and CES2 respectively (Crow et al., 2012). However, there are no in vitro studies
exploring the potency of CPS exposure on these noncholinergic targets in hepatocytes
under normal or steatotic conditions. Thus, the goal of the present study was to
determine the in vitro effects of CPS exposure on noncholinergic endpoints of OP
toxicity in the liver using cell culture models.
The current study utilized MCA hepatoma cells and rat primary hepatocytes as in
vitro hepatocyte models. MCA cells and primary hepatocytes have been widely utilized
as in vitro model systems to examine the effects of xenobiotics and hepatocyte lipid
metabolism. MCA cells are immortalized rat hepatoma cells that are phenotypically
stable and offer important advantages, such as ease of maintenance in culture, and
allow for long term exposures to toxic compounds (Rouimi et al., 2012). However, MCA
cells also have limitations to be considered during use, such as the potential loss of sexspecific gene expression and enzymatic activities, which may confer differential
sensitivities to pesticide induced effects (Donato et al., 1994). Primary hepatocytes,
freshly isolated from Sprague Dawley rats, serve as an “ex vivo” model of liver function
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to examine direct effects of CPS exposure on hepatocyte enzymes but they have a
limited life span. In addition, primary hepatocyte culture systems are limited because
some metabolic functions are not well preserved and loss of more than fifty percent of
the total metabolizing enzyme levels has been reported within 24 hours, particularly
enzymes involved in oxidative and post oxidative reactions (Davila et al., 1999; Donato
et al., 1994; Donato et al., 1992). Primary hepatocytes start to lose viability after 60
hours in culture as fifty percent of cells are dead along with decreased metabolic
functions and are not suitable for longer duration studies (Shenvi et al., 2008). MCA
cells, similar to primary hepatocytes, expressed CYP450 dependent activities
associated to phase-I xenobiotic metabolism but also retained the capacity to respond
to inducers (Donato et al., 1994). MCA cells are comparable to primary hepatocytes in
terms of lipoprotein metabolism and expression of molecular mediators of lipogenesis
(Chamberlain et al., 2013; Hansson et al., 2004).

2.2
2.2.1

Materials and Methods
Chemicals
CPS (≥99% purity) was purchased from Sigma-Aldrich (St. Louis, MO) and CPS

stock solutions were prepared in dimethyl sulfoxide (DMSO). CPO (99% purity) was
purchased from ChemService (West Chester, PA). AChE from Electrophorus electricus
(electric eel), glucose-6-phosphate dehydrogenase (G6P-DH), β-nicotinamide adenine
dinucleotide phosphate (NADP), and glucose-6-phosphate (G6P) were purchased from
Sigma-Aldrich (St. Louis, MO). Oleic acid (OA) and palmitic acid (PA) fatty acid stocks
were prepared in fatty acid-free 10% bovine serum albumin (BSA; Sigma-Aldrich, MO).
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2-AG (≥95% purity), AEA (≥98% purity), and arachidonic acid-d8 (AA-d8, ≥96% purity)
was purchased from Cayman (Ann Arbor, MI). The mobile phase solvents used for the
ultra performance liquid chromatography – tandem mass spectrometer (UPLC-MS/MS)
analysis were methanol (Optima ® LC/MS grade), water (Optima ® LC/MS grade), and
acetonitrile (Optima ® grade) purchased from Fisher Chemical (Thermo Fisher
Scientific, Waltham, MA). The supplements utilized for cell culture consisting of
Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park Memorial Institute (RPMI
1640) media, fetal bovine serum (FBS), sodium pyruvate, penicillin, and streptomycin
were purchased from Sigma-Aldrich (St. Louis, MO).

2.2.2

Immortalized cell culture
MCA hepatoma cells were obtained from American Type Culture Collection

(ATCC) and cultured as described previously (Howell et al., 2016). Briefly, MCA cells
were grown in DMEM with high glucose (4500 mg/L) containing glutamine (4 mM),
sodium pyruvate (1%), penicillin-streptomycin (1%) and 20% FBS. MCA cells were
maintained in an incubator at 37°C with 5% CO2 and passaged continuously when 70%
confluent. MCA cells were plated in rat tail collagen (0.025%) coated plates at a density
of 5x105 cells/ml and incubated overnight to allow for attachment to the surface prior to
starting treatments.
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2.2.3

Primary hepatocytes
As previously described, primary hepatocytes were isolated from male Sprague-

Dawley rats weighing approximately 250 grams (Howell et al., 2009). The cells were
isolated via collagenase perfusion of the liver. Briefly, each rat was anesthetized with a
continuous flow of oxygen containing isoflurane (2-5%). The depth of anesthesia was
measured by a tail pinch in which the rat no longer responds. The abdomen was
cleaned with ethanol and cut through the midline of the abdomen to expose the hepatic
portal vein. A blunt end cannula was then inserted through a cut in the portal vein. The
liver was flushed with Hank’s Balanced Salt Solution (HBSS) until it was blanched, and
this was repeated 2-3 times for each liver. The perfusion system, consisting of a pump
and a water bath, was then attached to the cannula. The liver was again flushed with
HBSS (1X) containing collagenase (Type I 100 U/ml) until the liver began to digest, as
evident by a loss of shape and a “honeycomb” type appearance due to breakdown of
connective tissue. The liver was then removed from the animal and cut into small pieces
and placed in a shaking water bath (37oC) for 5 minutes. After the liver homogenate
was passed through a sterile filter (100 microns) and centrifuged (100 x g, 2 minutes,
4°C), a pellet containing the hepatocytes was collected. The pellet was then
resuspended in media and passed through another sterile filter (70 microns). To further
purify the hepatocytes, the filtrate was then centrifuged (100 X g, 1 minute, 4°C) to form
a pellet, resuspended again in media, and centrifuged (100 X g, 1 minute, 4°C). This
process was repeated two times to further purify the hepatocyte fraction. The isolated
hepatocytes were then subjected to trypan blue staining to determine cell viability via
counting with a hemocytometer (Elam et al., 2001; Howell et al., 2009).
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Primary hepatocytes were plated in rat tail collagen (0.025%) coated 100 mm
petri dishes or 6-well plates at a density of 1x106 cells/ml. Cells were maintained in
growth media consisting of RPMI 1640 with 10% FBS, glucose (20 mM), insulin (100
nM), penicillin and streptomycin (1%), and treatment media containing RPMI 1640 with
BSA (0.5%), penicillin and streptomycin (1%). After plating, the cells were incubated for
3-4 hours to allow them to attach to the surface of the plate before starting treatments.

2.2.4

Experimental design
To determine the concentration dependent effects of CPS, MCA cells and

primary hepatocytes were exposed to CPS (0.002 µM, 0.02 µM, 0.2 µM, 2 µM, 20 µM)
for 8 or 24 hours and controls exposed to vehicle (DMSO; 0.025%) or control (without
CPS or DMSO). The selected CPS concentrations utilized in this study are based on a
previous study from our lab using MCA cells that were exposed to CPS (1.25 μM, 5 μM,
20 μM, 80 μM). In this previous study, exposure to CPS (5 μM) and higher
concentrations produced a significant increase in neutral lipid accumulation with no
cytotoxic effects (Howell et al., 2016). These low doses were comparable to a previous
study in hepatocytes where exposure to CPS (0.1 μM, 1 μM, and 10 μM) induced the
levels of CYP3A4, which is also a major CYP isoform involved in the bioactivation of
CPS (Rouimi et al., 2012). Additionally, the concentration range of CPS in this study is
comparable to the observed serum concentrations of CPS in cases of self-poisoning in
humans following acute CPS exposure where the peak serum concentrations are in the
low micromolar (<10 µM) range (Eddleston et al., 2005; Eyer et al., 2009).
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Fatty acid exposures were performed prior to the CPS treatments to induce
steatotic conditions and to determine the effect of high fat conditions on CPS toxicity. In
this study, we utilized a 2:1 ratio of OA (100 μM or 300 μM) and PA (50 μM or 150 μM)
mixture in 1% BSA and treated the cells for 24 hours. OA and PA are the two major fatty
acids highly available in western diets. The fatty acid concentrations used in this study
are based on previous studies that used these fatty acids to induce lipid accumulation
and steatotic conditions (Howell et al., 2016; Ricchi et al., 2009). Following 24 hours of
fatty acid exposure, cells were treated with media containing BSA (1%) only or vehicle
(0.025% DMSO) only or CPS (0.002 µM, 0.02 µM, 0.2 µM, 2 µM) for 8 hours in serum
free treatment media. Treatment media was serum free and contained DMEM or RPMI
1640 with fatty acid free BSA (0.5% or 1%), penicillin, and streptomycin (1%). RPMI
was supplemented with BSA in the treatment media to negate any confounding effects
of potential CPS degradation from FBS components. After the designated exposure
duration, cell monolayers were washed with phosphate buffered saline (PBS; pH 7.4),
cells were scraped and homogenates were made in Tris-HCl 50 mM (pH 7.4) buffer for
CES, MAGL, and FAAH activity assays.

2.2.5

Determining lipid accumulation by Oil Red O (ORO) staining
Following exposures, culture media was removed, and the cells were fixed with

10% buffered formalin for at least 30 minutes. Following fixation, cells were washed with
60% isopropanol and ORO stain (100 µl per well) was added for 15 minutes at room
temperature. Cells were then washed 4 times with deionized water and allowed to air
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dry. Intracellular ORO stain was extracted from the cells with 100% isopropanol and the
absorbance (520 nm) was measured to determine the amount of ORO. To normalize for
cell number following ORO staining, cell monolayers were stained with Janus Green for
5 minutes. Janus Green was extracted from the cells with 0.5 N HCl and the
absorbance was measured at 595 nm. The neutral lipid accumulation was expressed as
the ratio of ORO absorbance (520 nm) to Janus Green absorbance (595 nm) (Howell et
al., 2016).

2.2.6

CES continuous assay
Following the CPS treatments, cell lysates were homogenized according to the

procedure previously described (Ross et al., 2007). Briefly, hydrolysis reactions were
performed in a 96-well clear bottom plate with cell lysates diluted to 50 μg protein/ml
(final concentration) in 50 mM Tris-HCl buffer, pH 7.4 (150 µl final volume) based on the
protein values determined by Bradford protein assay. Lysates were preincubated for 5
minutes at 37°C and then the substrate para-nitrophenyl valerate (p-npv; final
concentration of 500 μM) was added to wells in triplicate to initiate the reaction. The
reaction was measured at 405 nm with 20 seconds intervals over 5 minutes to
determine the rate of formation for para-nitrophenol. The slopes of the activity curves
(absorbance units per minute) were calculated by using an extinction coefficient of 13
cm-1 mM-1, data were normalized to enzyme activity units and expressed as µmol
minute(min-1) mg protein (P-1) (Howell et al., 2018).
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2.2.7

MAGL and FAAH activity in cell lysates
Following the treatments, cell lysates were made as described above. Cell lysate

homogenates were diluted to the final protein concentration of 0.5 mg/ml in Tris-HCl
50mM buffer (pH 7.4) to a total reaction volume (100 µl) and pre-incubated for 5
minutes at 37°C. Following pre-incubation, samples were spiked with 2-AG (50 µM) or
AEA (50 µM) or 2% v/v ethanol (2 µl) as background and incubated for 30 minutes at
37°C. The reaction was then terminated with cold acetonitrile containing AA-d8 (2.5 µM)
and incubated for 10 minutes on ice. Samples were then centrifuged (10
minutes,10,000 x g, 40C) and the supernatant transferred to LC vials for UPLC-MS/MS
analysis of AA levels in the homogenates (Howell et al., 2018).
AA analysis was performed by UPLC-MS/MS. The mobile phases used were a
blend of component A (0.1% v/v acetic acid in water) and component B (0.1% v/v acetic
acid in acetonitrile). Samples (20 µl) were injected onto an Acquity UPLC BEH C18
column (1.7 µm, 100×2.1 mm I.D.) equipped with a guard column. The following
gradient program was set at a flow rate of 0.2 ml/minute for 20 minutes, eluting the
analytes with solvent (95% A, 5% B). Then the entire column eluate was directed into
the mass spectrometer via heated electrospray ionization in positive ion mode. AA was
observed by single reaction monitoring (SRM) and followed according to these settings:
AA, [M-H] - m/z 303.3 > 259.5, AA-d8, [M-H] - m/z 311.3 > 267.5. Scan times were 0.2
seconds per SRM and the scan width was 0.01 m/z. AA levels were quantified by
measuring the area under each chromatographic peak and comparing it to the area
under the chromatographic peak for the appropriate deuterated internal standard,
followed by correction for the ionization efficiency of AA relative to their deuterated
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standards (empirically determined) and data were expressed as the ratio of AA/AA-d8
(Carr et al., 2011).

2.2.8

Desulfuration assay
Bioactivation of CPS by CYP450 enzyme activity was determined by

desulfuration assay with hepatocyte microsomes which were not treated with CPS.
Preparation of cell microsomes and assay for CPS desulfuration were performed as
previously described with modifications (Chambers et al., 1989). Following the
treatments, cells were washed with PBS (pH 7.4) buffer and homogenized in 3 ml of
Tris-HCl 50 mM (pH 7.4). Cells were sonicated bursts for 10 seconds at 30% power 3
times and then centrifuged (17,000 x g, 15 minutes, 4°C). The collected supernatant
was centrifuged (100,000 x g, 1 hour, 4°C) again to obtain the microsomal pellet,
covered with glycerol storage buffer (20% v/v glycerol, 0.2 mM potassium EDTA, 0.1
mM potassium phosphate buffer, 0.5 mM dithiothreitol), and stored at -80°C until further
analysis. For the assay, cell microsomal pellets (0.2 µg/ml) were diluted in Tris-HCl 50
mM (pH 7.4) with magnesium chloride (5 mM) for a total reaction volume of 2 ml. The
formation of CPO was measured by monitoring the inhibition of the external source of
AChE which was from the electric eel. Eel AChE (0.2 U/ml, final concentration) was
added to the reaction with the NADPH-generating system, which consisted of NADP
(2.47 mg/ml), G6P (78.75 mg/ml) and G6P-DH (5 U/ml). This mixture was incubated
with the microsomes at 37°C for 30 minutes. CPS (80 µM) was included as the
substrate with the controls being ethanol (5 µl) and eserine sulfate (0.01mM). Then 1.75
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ml of Tris-HCl 50 mM (pH 7.4) buffer with acetylthiocholine (ATCh, 1 mM) was added to
initiate the reaction and incubated for 15 minutes at 37°C. The reactions were stopped
by adding a 4:1 (v/v) mixture of Sodium dodecyl sulfate:5,5-dithio-bis-(2-nitrobenzoic
acid) (SDS 0.5%:DTNB 0.0024 M) at 10 second intervals, and absorbance was read
spectrophotometrically at 412 nm.
CPO generated in the hepatocyte microsomes was quantified from a standard
curve of CPO concentrations versus electric eel AChE inhibition. A range of CPO
concentrations (1 x 10-5 M to 1 x 10-7 M) were used to result in AChE inhibition between
10% and 90%. Linear regression analysis was executed with the plot of the logit of
percent inhibition versus log10 oxon concentration. The best-fit line was drawn using
points corresponding to the 10-90% AChE inhibition range. The standard curve was
prepared three independent times using a unique set of reagents, and the data were
averaged to produce a single standard curve to use for the quantification of CPS
bioactivation to CPO. Data expressed as CPO nmol min-1 mg P-1.

2.2.9

Determination of IC50 values of CPS
The IC50 of a target compound indicates the concentration at which 50% of target

enzyme activity is inhibited at a specific substrate concentration. In this present study,
IC50 values of CPS exposure mediated inhibition was determined as an index of potency
for each target enzyme for 8 and 24 hour time points. The IC50 values were calculated
by the nonlinear regression method by plotting the sigmoidal curve between basal
concentration, with the lowest inhibition point (top) and the highest concentration with
maximum inhibition (bottom). The IC50 calculations are performed by executing the
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equations “dose response curves – inhibition” and “log (inhibitor) vs response - variable
slope”, using a four parameter dose response curve (4PL) with a variable slope model
in GraphPad PRISM 7 software. IC50 is the concentration of the CPS exposure that
gives a halfway response between the bottom and top of the inhibition points. The
calculated IC50 values from the data are expressed as nM or µM.

2.2.10

Statistical analysis
All the values in the data of the treatment and control groups at different time

points are presented as the mean ± standard error of the mean (SEM). Statistical
analysis of 2-AG and AEA hydrolysis assays was performed on transformed (log10
transformation) AA/AA-d8 ratios. The one-way analysis of variance (ANOVA) with a
Tukey’s post hoc test for multiple pairwise comparisons with a confidence interval of 95
percent was used to analyze the data for CPS concentration dependent inhibition of
enzyme activities. The statistical analysis for the data for steatotic or normal conditions
was analyzed by two-way ANOVA with Tukey's post hoc test using pairwise
comparisons. In experiments with just two groups, a Student’s t-test was used. A Pvalue less than or equal to 0.05 (P≤0.05) was used to indicate a statistical difference
between groups.
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2.3

Results

2.3.1

Concentration-dependent effects of CPS under normal conditions

2.3.1.1

Effect CPS on CES activity

The effect of CPS exposure on CES activity in both MCA cells and primary
hepatocytes was determined to assess the effect of exposure time on enzymatic activity
(Figure 1). The present data indicate MCA cells exposed to CPS from low to high
concentrations (0 µM to 20 µM) for 8 hours show a significant decrease in the CES
activity by 82% following exposure to the highest concentration of CPS (20 µM)
compared to vehicle (0 µM) (Figure 1A). Exposure to the lowest concentration of CPS
(0.002 µM) for 8 hours also significantly decreased CES activity by 30% compared to
the vehicle (Figure 1A). The next to the lowest concentration of CPS (0.02 µM) also
significantly decreased enzyme activity by 55% compared to the lowest concentration
CPS (0.002 µM), illustrating the concentration-dependent effect of CPS exposure on
CES activity. There was no significant increase or decrease in the inhibition of enzyme
activity between 0.02 µM to 20 µM concentrations in MCA cells when exposed for 8
hours (Figure 1A). Exposure to the highest concentration of CPS (20 µM) in primary
hepatocytes for 8 hours significantly decreased CES activity by 98% compared to the
vehicle and by 94% compared to CPS 0.02 µM. CES activity was significantly
decreased by 62% following exposure to CPS 0.2 µM compared to the next lowest CPS
concentration of 0.02 µM for 8 hours (Figure 1C). There were no significant differences
in the CES activities with the treatments of 0.002 µM or 0.02 µM compared to the
vehicle. There was no significant decrease in the enzyme activity between the CPS 0.2
µM and 2 µM concentrations.
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Exposure to CPS (0 µM to 20 µM) for 24 hours in MCA cells produced a
significant decrease in CES activity by 90% following exposure to CPS 20 µM compared
to the vehicle (Figure 1B). The lowest concentration of CPS (0.002 µM) also produced a
significant decrease in CES activity by 68% compared to the vehicle. Exposure to CPS
2 µM for 24 hours also significantly decreased CES activity by 57% compared to 0.002
µM while with CPS 20 µM significantly decreased CES activity by 68% compared to
CPS 0.002 µM. Exposure to CPS 0.02 µM produced a decrease in CES activity by 37%
compared to CPS 2 µM. There was no significant increase or decrease in enzyme
activity between CPS 0.02 µM to 20 µM exposures (Figure 1B). When primary
hepatocytes were exposed to CPS 20 µM for 24 hours, CES activity significantly
decreased by 97% compared to the vehicle (Figure 1D). Exposure to CPS 20 µM also
significantly decreased CES activity compared to CPS 0.2 µM in primary hepatocytes.
Additionally, exposure to CPS 0.2 µM produced a decrease in CES activity by 41%
compared to the 0.02 µM exposure in these cells. There was no significant alteration in
CES activity following exposure to the two lowest CPS concentrations (0.002 and 0.02
µM) for 24 hours compared to the vehicle in primary hepatocytes (Figure 1D).
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Figure 2.1

Concentration dependent effect of CPS exposure on CES activity in MCA
cells and primary hepatocytes.

Following 8 or 24 hours of CPS exposure in serum free media, CES activities were
determined in cell lysates by using para nitrophenyl valerate as a substrate. Data
represent the mean ± SEM of 4-6 independent replicates for MCA cells (A and B) and 45 animals for primary hepatocytes (C and D). Significant changes are denoted with
*P≤0.05 vs. 0, #P≤0.05 vs. 0.002.

2.3.1.2

Effect of CPS on FAAH activity

FAAH activity following exposure to CPS (0 – 20 µM) for 8 or 24 hours was
determined by hydrolysis of AEA assay in cell lysates of both MCA cells and primary
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hepatocytes (Figure 2). Exposure to the highest concentration of CPS (20 µM) for 8
hours significantly decreased FAAH activity by 96% compared to the vehicle (Figure
2A). There were no significant differences in FAAH inhibition following exposure to CPS
from 0.02 to 20 µM. However, exposure to CPS 0.02 µM significantly decreased FAAH
activity by 90% compared to the lowest concentration of CPS (0.002 µM) in these cells
(Figure 2A). There was no significant FAAH inhibition following exposure to the lowest
concentration of CPS (0.002 µM) for 8 hours in MCA cells (Figure 2A).
Exposure to CPS (20 µM) in primary hepatocytes for 8 hours significantly
decreased FAAH activity by 96% compared to vehicle (Figure 2C). The concentration
dependent effect of CPS exposure began at 0.2 µM producing a significant decrease in
the FAAH activity by 36% compared to CPS 0.02 µM. Additionally, exposure to CPS 2
µM decreased FAAH activity by 58% compared to exposure to CPS 0.2 µM in primary
hepatocytes. There was no significant alteration in FAAH activity following exposure to
the two lowest CPS concentrations (0.002 and 0.02 µM) for 8 hours in primary
hepatocytes. The FAAH activity in vehicle treated MCA cells was significantly
decreased by nearly 70% compared to the vehicle treated primary hepatocytes (Figure
2A & 2C).
FAAH activity following 24 hours of CPS exposure was determined in both MCA
cells and primary hepatocytes to evaluate the effects of prolonged CPS exposure on
FAAH activity. In MCA cells, exposure to CPS 20 µM for 24 hours significantly
decreased FAAH activity by 99% compared to vehicle (Figure 2B). Exposure to the
lowest concentration of CPS (0.002 µM) in MCA cells also significantly decreased FAAH
activity by 88% compared to the vehicle. There are no observed significant differences
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in enzyme activity between the exposures to CPS from 0.002 µM to 20 µM for 24 hours
in MCA cells.
As observed following exposure for 24 hours in primary hepatocytes, exposure to
CPS 20 µM significantly decreased FAAH activity by 81% compared to the vehicle in
primary hepatocytes (Figure 2D). Exposure to CPS 20 µM significantly decreased FAAH
activity by 74% compared to CPS 2 µM. There were no significant decreases observed
in the FAAH activity between vehicle to 2 µM following the 24 hours CPS exposure in
primary hepatocytes.
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Figure 2.2

Concentration dependent effect of CPS exposure on FAAH activity in MCA
cells and primary hepatocytes.

Following the CPS exposure for 8 or 24 hours in serum free media, hydrolysis of AEA
assay in cell lysates was determined as an index of the FAAH activity by analyzing the
ratio of AA/AA-d8 levels. Data represent the mean ± SEM of 4-6 independent replicates
for MCA cells (A and B) and 4-5 animals for primary hepatocytes (C and D). Statistical
analysis was performed on log10 transformed values. Significant changes are denoted
with *P≤0.05 vs. 0, #P≤0.05 vs. 0.02, &P≤0.05 vs. 2.

2.3.1.3

Effect of CPS on MAGL activity

MAGL activity following exposure to CPS (0 – 20 µM) for 8 or 24 hours was
determined in both MCA cells and primary hepatocytes by utilizing the 2-AG hydrolysis
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assay (Figure 3). Exposure to the highest concentration of CPS (20 µM) for 8 hours
significantly inhibited MAGL activity in MCA cells compared to vehicle (Figure 3A).
Exposure to CPS 0.2 µM also significantly decreased enzyme activity compared to CPS
0.02 µM. There were no observed differences in the enzyme activity when comparing
the vehicle and the two lowest concentrations of CPS (0.002 and 0.02 µM) or between
the three highest concentrations of CPS (0.2, 2, and 20 µM) in MCA cells.
Exposure to the highest concentration of CPS (20 µM) for 8 hours produced a
significant decrease in MAGL activity by 67% compared to vehicle in primary
hepatocytes (Figure 3C). Exposure to CPS 20 µM also produced a significant decrease
in the activity by 57% compared to CPS 2 µM. There was no significant effect on MAGL
activity between vehicle and the four lowest CPS concentrations (0.002, 0.02, 0.2, and 2
µM) at 8 hours of exposure in primary hepatocytes (Figure 3C). The activity of the
MAGL in the vehicle of MCA cells was decreased by 50% compared to the vehicle of
primary hepatocytes (Figure 3A & 3C).
MAGL activity following exposure to CPS (0 – 20 µM) for 24 hours was measured
to determine if prolonged exposure to CPS potentiated inhibition of MAGL in MCA cells
(Figure 3B). Exposure to the highest concentration of CPS (20 µM) significantly
decreased MAGL activity by 89% compared to vehicle in MCA cells. Exposure to CPS
0.02 µM for 24 hours produced a significant decrease in MAGL activity compared to
CPS 0.002 µM in MCA cells. Exposure to the lowest concentration of CPS (0.002 µM)
also significantly decreased MAGL activity compared to the vehicle. There were no
observed significant differences in MAGL activities between 0.02 µM to 20 µM in MCA
cells (Figure 3B).
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CPS exposure mediated inhibition of MAGL in primary hepatocytes following 24
hours of exposure was comparable to the currently observed inhibition following 8 hours
of CPS exposure (Figure 3D). Exposure to the highest concentration of CPS (20 µM)
significantly decreased MAGL activity compared to vehicle and the next lowest
concentration of CPS (2 µM). The maximal inhibition was 67% for CPS 20 µM
compared to vehicle. Exposure to CPS 2 µM and 0.2 µM significantly decreased MAGL
activity by approximately 16% compared to CPS 0.02 µM and by approximately 20%
compared to vehicle. There were no significant changes in MAGL activity between
vehicle or CPS 0.002 µM and CPS 0.02 µM in primary hepatocytes (Figure 3D).
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Figure 2.3

Concentration dependent effect of CPS exposure on MAGL activity in MCA
cells and primary hepatocytes.

Following 8 or 24 hours CPS exposure in serum free media, hydrolysis of 2-AG assay in
cell lysates was determined as an index of the MAGL activity by analyzing the ratio of
AA/AA-d8 levels. Data represent the mean ± SEM of 4-6 independent replicates for
MCA cells and 4-5 animals for primary hepatocytes. Statistical analysis was performed
on log10 transformed values. Significant changes are denoted with *P≤0.05 vs. 0,
#P≤0.05 vs. 0.002.
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2.3.1.4

Determining the IC50 values of CPS on enzyme activities

In MCA cells, the IC50 value for the inhibition of CES activity for 8 hours of CPS
exposure is 3.3 nM and in primary hepatocytes, it is 0.15 µM (Table 1 & 2). Inhibition of
the CES following CPS exposure for 24 hours produced an IC50 of 0.18 µM in primary
hepatocytes (Table 2). The IC50 value for the FAAH activity following CPS exposure for
8 hours in MCA cells is 5.2 nM and in primary hepatocytes is 0.96 µM (Table 1 & 2).
IC50 of FAAH activity following exposure to CPS for 24 hours in MCA cells was
determined to be 0.705 nM (Table 1). The inhibition of MAGL following CPS exposure
for 8 hours in MCA cells produced a calculated IC50 value of 17.9 nM (Table 1).
Inhibition of MAGL following CPS exposure for 24 hours yielded an IC50 of 1.46 nM in
MCA cells (Table 1). It should be noted that there were not enough data points in the
appropriate concentration range to accurately calculate the IC50 values for CES activity
in MCA cells following CPS exposure for 24 hours, FAAH activity in primary hepatocytes
following CPS exposure for 24 hours, and MAGL activity in primary hepatocytes
following CPS exposure 8 and 24 hours (Table 1 & 2). Thus, these IC50 values are not
available (N/A).
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Table 2.1

IC50 values of CES, FAAH and MAGL activities in MCA cells following 8 or
24 hours CPS exposure.

IC50 values calculated based on the concentration dependent studies following the
CPS exposure. (N/A=not available).

Table 2.2

IC50 values of CES, FAAH, and MAGL activities in primary hepatocytes
following CPS exposure for 8 or 24 hours.

IC50 values calculated based on the concentration dependent studies following the
CPS exposure. (N/A=not available).

2.3.2

Effects of steatotic conditions on CPS toxicity

2.3.2.1

CPS effect on neutral lipid accumulation

Following fatty acid exposure and CPS treatments for 8 hours, neutral lipid
accumulation was determined by ORO staining (Figure 4). OA:PA (300 µM:150 µM) in
MCA cells produced a significant increase in neutral lipid accumulation compared to
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control and vehicle treated cells (Figure 4A). However, CPS exposure did not produce
any effect on the neutral lipid accumulation in MCA cells. OA:PA (300 µM:150 µM)
produced a significant increase in neutral lipid accumulation in primary hepatocytes and
CPS exposure did not have any effect on lipid accumulation compared to control and
vehicle treated normal cells (Figure 4B).
B

A

Figure 2.4

Concentration dependent effect of fatty acids to induce lipid accumulation
in MCA cells and primary hepatocytes.

Neutral lipid accumulation was determined with ORO staining in MCA cells and primary
hepatocytes pretreated in serum free or fatty acid media for 24 hours and exposed to
CPS for 8 hours. Data represent the mean ± SEM of 7-9 independent replicates for
MCA cells (A) and 5-6 animals for primary hepatocytes (B). *P≤0.05 vs. Control
(Normal), #P≤0.05 vs. 0 µM (Normal).

2.3.2.2

Bioactivation capacity over the duration of exposures

The bioactivation of CPS in hepatocytes mediated by CYP450 was determined
by ex vivo formation of CPO with the desulfuration assay in cell microsomes (Figure 5 &
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6). The bioactivation capacity of cell microsomes was determined from the cells
collected at 0 hours, 24 hours, and 48 hours. The cells were treated with fatty acids for
the first 24 hours then fatty acid containing media was replaced with normal treatment
media for an additional 24 hours producing a maximal culture time of 48 hours. The
bioactivation capacity in MCA cells significantly decreased after 24 hours and 48 hours
in normal conditions compared to the 0 hour starting time point (Figure 5A). The
bioactivation capacity in primary hepatocytes significantly decreased after 24 hours, but
no significant difference observed after 48 hours in normal conditions compared to the 0
hour starting time point (Figure 5B). However, there was no significant difference
between the 24 and 48 hours time points in MCA cells or primary hepatocytes,
indicating no loss of bioactivation capacity between these time intervals. Additionally,
fatty acid exposure did not significantly alter the bioactivation of CPS in MCA cells or
primary hepatocytes (Figure 6A & 6B).
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Time course of bioactivation capacity of CPS determined by desulfuration
assay in MCA cells and primary hepatocytes.

Bioactivation capacity of cell microsomes prepared from MCA cells and primary
hepatocytes (in serum free treatment media) to determine the ex vivo formation of CPO
in normal conditions. Data represent the mean ± SEM of 5 independent replicates for
MCA cells (A) and 5 animals for primary hepatocytes (B). *P≤0.05 vs. 0 hours.
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Effect of steatosis on bioactivation capacity of CPS determined by
desulfuration assay in MCA cells and primary hepatocytes.

Bioactivation capacity of cell microsomes prepared from MCA cells and primary
hepatocytes (in serum free or fatty acid treatment media) to determine the CPO
formation in normal and high fat conditions. Data represent the mean ± SEM of 5
independent replicates for MCA cells (A) and 5 animals for primary hepatocytes (B).

2.3.2.3

Effect of steatotic conditions on CPS inhibition of CES activity

Following exposure to CPS in both normal conditions and steatotic conditions,
CES activity was determined in cell lysates (Figure 7). Steatotic MCA cells had a
significant decrease in CES activity following exposure to the lowest concentration of
CPS (0.02 µM) and higher concentrations compared to the vehicle (Figure 7A). Normal
MCA cells had a significant decrease following exposure to CPS 0.2 µM and higher
concentrations. CES activity was significantly decreased within CPS treatment groups in
steatotic MCA cells and showed more sensitivity to CPS mediated inhibition of CES
compared to normal MCA cells. Exposure to CPS 2 µM in primary hepatocytes
produced a significant decrease in CES activity (Figure 7B). However, unlike in the
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MCA cells, there were no significant effects of steatotic conditions on CPS exposure
mediated CES inhibition in primary hepatocytes.
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Effect of steatotic conditions on CPS inhibition of CES activity in MCA cells
and primary hepatocytes.

CES continuous activity assay were determined in cell lysates (100 µg/ml) of normal
(cells pretreated for 24 hours in serum free media) and steatotic conditions (cells
pretreated for 24 hours in fatty acid media), following 8 hours CPS exposure by using pnpv as a substrate. Data represent the mean ± SEM of 4-5 independent replicates for
MCA cells (A) and 5-6 animals for primary hepatocytes (B). For MCA *P≤0.05 vs. 0
(Normal), &P≤0.05 vs. 0 (OA:PA, 300:150 µM), #P≤0.05 vs. to the corresponding
Normal concentration of CPS.

2.3.2.4

Effect of steatotic conditions on CPS inhibition of FAAH activity

Following CPS exposure in both normal and steatotic conditions, FAAH activity
was significantly decreased following exposure to CPS 0.02 µM and higher
concentrations in MCA cells (Figure 8A). However, primary hepatocytes were less
sensitive to FAAH inhibition following CPS exposure compared to MCA cells. Exposure
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to CPS 2 µM in primary hepatocytes produced a significant decrease in both normal and
steatotic conditions (Figure 8B). Thus, there were no significant effects of the steatotic
conditions on CPS mediated inhibition of FAAH activity in MCA cells or primary
hepatocytes.
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Effect of steatotic conditions on CPS inhibition of FAAH activity in MCA
cells and primary hepatocytes.

Hydrolysis of AEA assay in cell lysates of normal (cells pretreated for 24 hours in serum
free media) and steatotic conditions (cells pretreated for 24 hours in fatty acid media)
was determined following 8 hours of CPS exposure as an index of the FAAH activity by
analyzing the ratio of AA/AA-d8 levels. Data represent the mean ± SEM of 4-5.
independent replicates for MCA cells (A) and 4-6 animals for primary hepatocytes (B).
Statistical analysis was performed on log10 transformed values. *P≤0.05 vs. 0 (Normal),
&P≤0.05 vs. 0 (OA:PA, 300:150 µM), @P≤0.05 vs. 0.2 (Normal), %P≤0.05 vs. 0.2
(OA:PA, 300:150 µM).
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2.3.2.5

Effect of steatotic conditions on CPS toxicity with MAGL activity

MAGL activity was determined in cell lysates following exposure to CPS in
normal or fatty acid induced steatotic conditions in both MCA cells and primary
hepatocytes (Figure 9). Following CPS exposure for 8 hours, there was significant
inhibition of MAGL activity following exposure to CPS 0.02 µM and higher
concentrations in both normal and steatotic MCA cells (Figure 9A). There was no
significant effect of steatotic conditions on MAGL activity following exposure to CPS in
MCA cells. Following exposure to CPS 2 µM, there was a significant decrease in both
normal and steatotic primary hepatocytes compared to lower concentrations of CPS
(Figure 9B). However, steatotic primary hepatocytes were less sensitive to MAGL
inhibition and as indicated by lower inhibition following exposure to CPS 2 µM when
compared to normal cells.
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Effect of steatotic conditions on CPS inhibition of MAGL activity in MCA
cells and primary hepatocytes.

Hydrolysis of 2-AG assay in cell lysates of normal (cells pretreated for 24 hours in
serum free media) and steatotic conditions (cells pretreated for 24 hours in fatty acid
media) was determined following 8 hours of CPS exposure as an index of the MAGL
activity by analyzing the ratio of AA/AA-d8 levels. Data represent the mean ± SEM of 45 independent replicates for MCA cells (A) and 4-6 animals for primary hepatocytes (B).
Statistical analysis was performed on log10 transformed values. *P≤0.05 vs. 0 (Normal),
&P≤0.05 vs. 0 (OA:PA, 300:150 µM), @P≤0.05 vs. 0.2 (Normal), %P≤0.05 vs. 0.2
(OA:PA, 300:150 µM), #P≤0.05 vs. to the corresponding Normal concentration of CPS.
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2.4

Discussion
There were no in vitro studies examining the direct exposure of CPS on

noncholinergic targets of OP toxicity under normal and induced steatotic conditions in
hepatocytes. Thus, the present study was the first to examine if CPS exposure inhibits
these noncholinergic endpoints in vitro and if increase in neutral lipid accumulation
within the hepatocyte alters this inhibition. Exposure to OP insecticides, including CPS,
has been associated with metabolic disease conditions such as hypertriglyceridemia
and hepatic steatosis (Howell et al., 2016; Slotkin et al., 2005). These effects on lipid
metabolism may be due to the inhibition of non-cholinergic target endpoints (Howell et
al., 2016; Slotkin et al., 2005). Hepatic steatosis is the main characteristic of NAFLD.
This increase in neutral lipid accumulation within the hepatocyte can occur due to an
increase in circulating free fatty acids (FFA) which result in increased uptake of FFAs
and caused metabolic alterations including DNL, fatty acid oxidation, and VLDL
secretion in the hepatocyte (Fabbrini et al., 2010). OA and PA are the major fatty acids
available in western diets and in vitro studies showed that utilization of the fatty acids in
2:1 ratio increased lipid accumulation (Ricchi et al., 2009). In our current study, we
utilized OA:PA (300:150 μM) and incubated for 24 hours prior to CPS treatments to
induce steatotic conditions. This concentration increased neutral lipid accumulation in
both MCA cells and primary hepatocytes which is mainly due to the accumulation of
triglycerides and cholesteryl esters.
The liver is the major organ involved in glucose, lipid, and xenobiotic metabolism.
The liver is also the primary site of the first-pass metabolism of CPS metabolism when
administered via the oral route. Hepatocytes are the main cell type in the liver that are
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involved in major metabolic activities, such as metabolism of lipids and most
xenobiotics, including CPS. CPS is metabolized in the liver by different pathways
including bioactivation and detoxication processes. Primary hepatocytes are freshly
isolated and used as an ex vivo model of the liver function and are widely used as a
model for the study of the metabolism of xenobiotics and mechanism of toxicity, but the
primary hepatocyte cultures lose the CYP450 activity associated to the phase I activities
and their application is limited to short term studies (Donato et al., 1994). MCA cells are
immortalized cells and also used as an in vitro model to examine hepatocyte lipid
metabolism because their lipoprotein metabolism and expression of molecular
mediators of lipogenesis are similar to primary hepatocytes (Chamberlain et al., 2013;
Boren et al., 1994). Our previous studies in MCA cells demonstrated exposure to CPS
increased free fatty acid-induced intracellular lipid accumulation, which is maybe due to
inhibition of hepatic serine hydrolases including CES, FAAH, and MAGL (Howell et al.,
2016). Therefore, in this current study, we utilized MCA cells and rat primary
hepatocytes to examine the selective potency of CPS on targets of OP toxicity, the
effect of steatotic conditions on CPS mediated toxicity, and bioactivation of CPS
(Donato et al., 1994; Holme, 1985). The metabolism of OP insecticides mainly relies on
the cytochrome P450 system in hepatocytes for bioactivation or detoxication of
insecticides (Tang et al., 2001). The presence of hepatic steatosis and lipid
accumulation in humans and rats has been shown to decrease CYP450 isozyme
(CYP2A, 3A, 2E) expression and metabolic activity (Donato et al., 2006). In this study,
the bioactivation capacity of CPS in microsomes was decreased after 24 hours. In
addition, there were no significant changes observed after 48 hours under normal
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conditions in both MCA cells and primary hepatocytes. In a previous study which
examined the enzyme activities involved in phase I and phase II metabolism using
various cell culture models, including primary hepatocytes and MCA cells, the rodent
hepatoma cells expressed CYP450 dependent activities and also retained the capacity
to respond to the inducers after 24 hours in culture (Donato et al., 1994).The currently
observed decrease in the bioactivation of CPS after 24 and 48 hours in both cell types
may be due to the cells being serum starved and experiencing the loss of enzymatic
functional capacity such as CYP450 enzyme activities. However, the steatotic
conditions in both MCA cells and primary hepatocytes did not show any significant
effect on the bioactivation of CPS; this shows that steatotic hepatocytes did not affect
the formation of CPO.
The CES belongs to the serine hydrolase family and it is highly expressed in the
liver and also present in plasma (Ross et al., 2007; Satoh et al., 1998). One of the major
functions of CES is known to be the metabolism of xenobiotics, including OP oxon
metabolites such as CPO, and it is also involved in lipid metabolism (Lehner et al.,
2012). Crow et al. (2012) examined the selective potency of CPO mediated inhibition of
recombinant human CES1 and CES2 isoforms in vitro and demonstrated that 50
percent of the enzyme activity was inhibited with 0.15 nM for CES1 and 0.33 nM for
CES3 (Crow et al., 2012). In the current study, under normal conditions, CPS (0.002
μM) exposure for 8 hours and 24 hours produced significant inhibition in overall CES
activity by 30% and 68% in MCA cells and in primary hepatocytes, respectively.
Following CPS (0.2 μM) exposure for 8 and 24 hours in primary hepatocytes, CES
activity was significantly inhibited by 65% and 48%, respectively. The sensitivity of CES
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in steatotic primary hepatocytes is not comparable to steatotic MCA cells with regards to
enzymatic activity following CPS exposure. Steatotic MCA cells had increased inhibition
of CES following CPS exposure but there was no significant effect of steatotic
conditions on CES inhibition following CPS exposure in primary hepatocytes. Previous
studies have demonstrated that inhibition of CES activities has effects on steatotic
conditions in both in vitro and in vivo conditions, such as increased TG accumulation
and decreased VLDL assembly and secretion (Dolinsky et al., 2004; Ko et al., 2009;
Lehner et al., 1999). Therefore, inhibition of CES following exposure to CPS may
increase lipid accumulation and steatotic conditions along with increased CES inhibition
may increase the severity of the disease condition. Following CPS exposure, the IC50
values for the inhibition of CES activity in MCA cells (3.3 nM) are in the lower nM range
compared to CES activity in primary hepatocytes (150 nM) following exposure to CPS
for 8 hours. A recognized limitation of this study is that the overall CES activity in the
vehicle (DMSO) groups of the MCA cells are lower when compared to primary
hepatocytes which indicate that higher sensitivity in MCA cells following CPS exposure,
which is maybe due to a decreased number of available CES active sites to be inhibited
by CPO in MCA cells than primary hepatocytes.
The endogenous ECB system consists of the two major cannabinoids, 2-AG and
AEA. These are lipid mediators that are produced on demand and bind locally to
specific G-protein coupled receptors, CB1 and CB2. As previously mentioned, their
physiological actions are terminated by hydrolyzing 2-AG and AEA primarily by MAGL
and FAAH, respectively. MAGL is the major hydrolytic enzyme of 2-AG; however, 2-AG
can also be hydrolyzed by CES and FAAH (Carr et al., 2011; Di Marzo, 2008).
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Cannabinoid receptors are expressed in the normal liver but they are highly expressed
during altered physiological conditions such as hepatic steatosis (Osei-Hyiaman et al.,
2005). The ECB system is involved in fat metabolism in the liver by upregulation of
lipogenic gene expression which leads to an increase in DNL (Osei-Hyiaman et al.,
2005). Earlier studies demonstrated that OP oxon metabolites, including CPO, inhibited
the ECB metabolizing enzymes FAAH and MAGL (Quistad et al., 2006). Quistad et al.
(2006) determined the CPO potency of FAAH and MAGL in mouse brain homogenates
was 80 nM and 34 nM for FAAH and MAGL, respectively (Quistad et al., 2006). The
current study demonstrated that in normal and steatotic conditions, CPS mediated
inhibition (most likely due to bioactivation of CPS to CPO) of FAAH is observed
following exposure to CPS 0.02 μM and 0.2 μM for 8 hours in MCA cells and primary
hepatocytes, respectively. However, the inhibition of MAGL is observed following
exposure to CPS 0.2 μM in MCA cells and CPS 20 μM in primary hepatocytes which
indicate FAAH is more sensitive than MAGL in these two cell culture models. Inhibition
of FAAH and MAGL following CPS exposure in rats results in the induction of ECB
levels (Carr et al., 2011). Previous studies demonstrated treatments with agonists of
CB1 and CB2, increased the degree of OA induced steatosis in HepG2 and
immortalized human hepatocytes in a concentration dependent manner (De Gottardi et
al., 2010). In the current study, exposure to CPS in MCA cells and primary hepatocytes
produced significant inhibition of MAGL and FAAH after 8 and 24 hours, which may lead
to an increase in ECB levels. An increase in ECB levels could increase the activation of
CB1 receptors and, in turn, increase DNL. Thus, in summary, the current steatotic
conditions did not produce any significant effect on CPS mediated inhibition of FAAH
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activity in MCA cells and primary hepatocytes. MAGL is less sensitive in steatotic
primary hepatocytes than MCA cells. The disruption of FAAH and MAGL activities
following CPS exposures may increase the severity of the steatosis by increasing the
levels of 2-AG, which leads to the activation of cannabinoid receptors.
As noted, the range of CPS which was used in the current study went from 0.002
to 20 µM. The low μM range of concentrations in our study is comparable to the in vitro
study where the CPS effects on detoxication systems in hepatocytes were examined
(Howell et al., 2016; Rouimi et al., 2012). In addition, these levels are comparable to the
peak serum concentrations of CPS (<10 μM) in humans following intentional or
accidental exposure to CPS (Eddleston et al., 2005). The current range of CPS
concentrations produced marked inhibition of the hepatic serine hydrolases. The
sensitivities of the target enzymes in the hepatocytes following CPS exposure in the
rank order of CES>FAAH>MAGL was determined in the present study. This rank order
is comparable to the previously reported sensitivities from both our lab and others
(Casida et al., 2005; Howell et al., 2018). Data from our lab demonstrated hepatic CES
and FAAH are more sensitive to inhibition than hepatic MAGL following subacute
exposure to CPS (2 mg/kg) for 10 days via oral gavage in C57BL/6J mice (Howell et al.,
2018).

2.5

Conclusion
The present in vitro studies examining the sensitivities of the OP targets indicate

hepatic CES is the most sensitive of the noncholinergic endpoints and are consistent
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with other studies in the literature. The inhibition of CES following CPS exposure was
more sensitive in steatotic MCA cells whereas MAGL was less sensitive in steatotic
primary hepatocytes compared to normal primary hepatocytes. The capacity of MCA
cells and primary hepatocytes to bioactivate CPS appeared to be decreased after 24
hours but did not change from 24 to 48 hours. The current data indicate the presence of
steatotic conditions increases inhibition of hepatic serine hydrolases following CPS
exposure. However, it is not known if this in vitro phenomenon can be extrapolated to
an in vivo model. Thus, the currently observed effects of CPS on noncholinergic
endpoints of OP toxicity in two cell culture based models should be further explored in a
whole animal model of obesity to provide more physiological relevance.
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CHAPTER III
DETERMINE THE EFFECTS OF OBESITY ON CHOLINERGIC AND
NONCHOLINERGIC ENDPOINTS OF ORGANOPHOSPHATE
(OP) TOXICITY FOLLOWING THE ACUTE EXPOSURE
TO CHLORPYRIFOS (CPS) IN VIVO.

3.1

Introduction
The prevalence of obesity has risen alarmingly in the United States. As of 2017,

39.8% of adults (20 years of age or older), 18.4% of children (6-11 years of age), and
20.6% of adolescents (12-19 years of age) are classified as being obese with a BMI ≥
30 kg/m2 (Hales et al., 2020; Ogden et al., 2015). Obesity is often associated with comorbidities such as type 2 diabetes, NAFLD, and cardiovascular diseases (Paschos et
al., 2009; Van Gaal et al., 2006). Several recent epidemiological studies have shown
that exposure to environmental chemicals such as organochlorine (OC) or OP
pesticides, including CPS, may contribute to the increase in the prevalence of obesity
and diabetes (Lee, 2012; Lee et al., 2014; Malekirad et al., 2013; Montgomery et al.,
2008; Raafat et al., 2012). Although there are studies that have examined the links
between pesticide exposure and the development of obesity and type 2 diabetes (or
their increased severity), there is a dearth of studies that have examined whether obese
and lean subjects exposed to pesticides, especially OPs, exhibit a similar degree of
toxicity or whether toxicity is modulated by the obese phenotype.
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A recent study by Lee et al. (2014) revealed BMI is a prognostic indicator of
poisoning severity in OP poisoned patients, especially those exposed to highly lipophilic
OPs (Lee et al., 2014). When compared to normal weight individuals, obese individuals
have altered pathophysiological conditions such as increased adiposity, increased fat
mass, potentially altered basic metabolic rates, and alterations in xenobiotic
metabolism. While these metabolic alterations accompanying obesity are well known,
the effects of obesity on OP pesticide toxicity in terms of cholinergic and noncholinergic
effects have not been extensively evaluated.
As previously mentioned, OPs comprise nearly fifty percent of all pesticide usage
in the United States and CPS is the most widely used OP for agriculture purposes
(Grube et al., 2011; Solomon et al., 2014). The primary acute neurotoxic target of the
OPs is the alteration of the cholinergic system via inhibition of acetylcholinesterase
(AChE), whereas noncholinergic targets of OPs include other serine hydrolase enzymes
such as monoacylglycerol lipase (MAGL), fatty acid amide hydrolase (FAAH) and
carboxylesterases (CES) (Casida et al., 2004, 2005; Quistad et al., 2006; Quistad et al.,
2001; Ross et al., 2010). As previously mentioned, CES is a large family of enzymes
that catalyze the hydrolysis of substrates containing ester and amide bonds, including
both xenobiotic and endobiotic substrates (Ross et al., 2010). Murine Ces1d or human
CES1 plays an important role in the delivery of lipid substrates for the assembly of
apolipoprotein B (apoB) containing lipoproteins. CES3 is also a major lipase in adipose
tissue where it catalyzes the hydrolysis of triglycerides into glycerol and free fatty acid
which contributes to elevated circulating free fatty acids (Quiroga et al., 2012; Ross et
al., 2010).
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Given the lack of studies examining the effects of obesity on OP toxicity, the
present study was designed to evaluate the in vivo effects of acute exposure to CPS in
mice, which had been fed either a standard chow diet or high fat diet for four weeks
prior to CPS treatment to induce obesity. To conduct a global assessment of OP
toxicity, the selected endpoints included both cholinergic and noncholinergic OP targets.
Cholinergic endpoints were assessed by determining AChE activity in the central
nervous system (CNS) and periphery (RBC and skeletal muscle). Inhibition of CES,
MAGL, and FAAH activities was evaluated in the liver of CPS-treated mice as indices of
noncholinergic toxicity. The effect of high fat diet on CPS bioactivation to chlorpyrifosoxon (CPO) in the liver microsomes mediated by CYP450 isozymes was determined by
the desulfuration assay. Expression of hepatic CYP450 isoforms that are involved in
CPS bioactivation was determined by real time-polymerase chain reaction (rt-PCR)
analysis as an additional measure to determine the effect of diet or CPS exposure on
bioactivation capacity. Major detoxication metabolite, 3,5,6-trichloro-2-pyridinol (TCP),
levels were measured in the liver to determine the detoxication capacity of the liver to
form TCP by dearylation of CPS and/or hydrolysis of CPO. We focused on the liver
given its central roles in CPS and nutrient metabolism and because of the prevalence of
noncanonical serine hydrolase targets of OPs in this tissue.

3.2
3.2.1

Materials and Methods
Animal care and materials
Male C57BL/6J mice (4 weeks of age; n=32) were purchased from Jackson

Laboratories and allowed to acclimate for one week prior to experimental manipulation.
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Animals were group housed at Mississippi State University (MSU) College of Veterinary
Medicine in Association for Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) approved animal facilities and allowed access to food and water
ad libitum unless otherwise stated. All animal protocols were approved by the MSU
Institutional Animal Care and Use Committee (IACUC) prior to implementation.
CPS (≥99% purity) purchased from Sigma-Aldrich (St. Louis, MO), stock
solutions of CPS were prepared in corn oil for animal dosing. CPO (99% purity), TCP
(>99% purity) and simazine (>99% purity) were purchased from Chem Service (West
Chester, PA). 2-arachidonyl glycerol (2-AG, ≥95% purity), anadamide (AEA, ≥98%
purity), and arachidonic acid-d8 (AA-d8, ≥96% purity) were purchased from Cayman
Chemicals (Ann Arbor, MI). The solvents used for CPS and TCP analysis by ultra
performance liquid chromatography – tandem mass spectrometer (UPLC-MS/MS) were
methanol (Optima® LC-MS grade), water (Optima® LC-MS grade), ethyl acetate
(Optima® LC-MS grade ), and acetic acid (Optima® LC-MS grade) which were
purchased from Fisher Chemical (Thermo Fisher Scientific, Waltham, MA). Blood
collection tubes (BD Vacutainers) were purchased from Becton, Dickinson and
Company (Franklin Lakes, NJ).

3.2.2

Experimental design
Mice (5 weeks of age) were fed standard rodent chow diet (Teklad 18% protein

rodent diet) or high fat diet (60% kcal from lard; Research Diets) for 4 weeks to induce
obesity and alterations in systemic lipid metabolism. Immediately following 4 weeks of
standard diet or high fat diet intake, animals were treated with CPS (2.0 mg/kg;
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n=8/group) or vehicle (corn oil; 1 ml/kg; n=8/group) by oral gavage then fasted for 12
hours. The present dose of 2.0 mg/kg was utilized to inhibit ChE activity in plasma and
AChE activity in RBCs, but not in the CNS, because plasma ChE and RBC AChE
activities are more sensitive to CPS mediated inhibition than CNS AChE activities
(Zheng et al., 2000). After 12 hours of fasting, animals were euthanized by carbon
dioxide (CO2) asphyxiation then blood was drawn by cardiac puncture and collected into
blood collection tubes containing sodium heparin (BD vacutainers). Tissues (brain,
skeletal muscle, liver, and adipose) were harvested, snap frozen in liquid nitrogen, and
stored at -80˚C for further analysis.

3.2.3

Metabolic phenotyping
Basic metabolic phenotyping was performed as previously described (Howell et

al., 2014; Mulligan et al., 2017). Before sacrifice, fasting blood glucose measurements
were obtained via handheld glucometer (Alphatrak II; Bayer Animal Health).
Immediately following sacrifice, heparinized blood was centrifuged to separate the RBC
fraction and plasma. The plasma was utilized to determine circulating fasting insulin
(Ultrasensitive Mouse Insulin ELISA; Crystal Chem), triglyceride (Triglyceride assay,
Cayman Chemical), and total cholesterol (Amplex Red Total Cholesterol Assay; Life
Technologies) levels. Hepatic triglyceride content (Cayman Chemical) was measured to
quantify the degree of hepatic steatosis and expressed as micromoles of triglyceride per
mg of protein (µmoles TG/ mg P-1) as previously performed (Howell et al., 2014;
Mulligan et al., 2017).
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3.2.4

Determination of CPS exposure on cholinesterase activity
AChE activities in RBC, brain, and skeletal muscle, as well as ChE activities in

plasma, were determined by a modification of the Ellman method (Chambers et al.,
1989; Ellman et al., 1961). The RBC AChE activity or plasma ChE activity was done by
continuous AChE activity assay as previously described (Chambers et al., 1993).
Briefly, RBC samples were diluted (1:3) in sodium phosphate buffer (SPB) (0.1 M, pH
7.4 at 370C). The assay was performed in 96-well clear bottom plates in triplicates of
RBC or plasma samples (5 µl) with a final concentration of 0.0005 μl/ml. Briefly, to
determine the amount of AChE, RBCs were exposed to SPB (0.1 M, 235 µL) containing
5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB; 0.33 mM, 30 µl) and acetylthiocholine
(ATCh) diluted in SPB (1 mM, 30 µl), serving as a chromogen and as a substrate,
respectively. Absorbance was measured at 15-minute intervals for a total of 60 minutes
at 412 nm.
AChE activity in the brain and skeletal muscle tissues were measured by
discontinuous AChE activity assay as previously described. Briefly, tissues (100 mg)
were homogenized in 0.05 M Tris-HCl (pH 7.4 at 37°C) and homogenates (brain 1
mg/ml and skeletal muscle 2.5 mg/ml) were pre-incubated at 37°C for 15 minutes. ATCh
(1 mM final concentration) was added as a substrate and the mixture was incubated for
15 minutes. The reaction was terminated with 250 μl with final concentrations of Sodium
dodecyl sulfate:5,5-dithio-bis-(2-nitrobenzoic acid) (SDS 0.5%:DTNB 0.0024 M) mixture
(4:1, v/v). Absorbance was measured at 412 nm. Protein concentration was determined
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by the Bradford assay by using BSA and activity expressed as nmol/min/mg protein (P)
(Bradford, 1976).

3.2.5

Determination of CPS exposure on plasma arylesterase activity
Paraoxonase (PON) activity was determined in plasma by using phenyl acetate

as a substrate (Davis et al., 2009; Gan et al., 1991). Briefly, each plasma sample (2 μl)
was added to two wells of a microtiter plate containing EDTA buffer (198 μl, 1 mM
EDTA with Tris-HCl 0.1M, pH 8.0) as blank and two wells containing calcium buffer (198
μl, 2 mM CaCl₂, Tris-HCl 0.1 M, pH 8.0) and the plate pre-incubated for 5 minutes at
37˚C. Phenyl acetate (2 μl, 50 mM in ethanol) was then added to each well to initiate the
reaction and absorbance measured every 15 seconds for 2 minutes at 270 nm. The
data are expressed in units/min/ml by subtracting averages of the EDTA blanks from the
calcium buffer containing wells.

3.2.6

Determination of CPS exposure on hepatic, adipose, and plasma CES
activities
CES continuous assay was utilized to measure the activities in both the tissue

homogenates and plasma (Crow et al., 2008; Ross et al., 2007). The CES assay was
performed with tissue homogenates or plasma samples diluted to 100 μg protein/ml
based on the protein values determined by Bradford protein assay. The assay was
performed as explained in Chapter-2 by using p-npv as the substrate, added at a final
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concentration of 500 μM and data were normalized to enzyme activity units, expressed
as µmol min-1 mg P-1 (Ross et al., 2007).

3.2.7

Measurement of hepatic MAGL and FAAH activities
The hydrolysis of the endogenous endocannabinoids 2-AG and AEA was utilized

to determine if CPS exposure alters the activities of the serine hydrolases primarily
responsible for their degradation, MAGL, and FAAH, respectively, as previously
described in Chapter 2 (Carr et al., 2013; Carr et al., 2014). Briefly, tissue homogenates
were diluted to the final protein concentration of 0.5 mg/ml in Tris-HCl (50 mM, pH 7.4)
and pre-incubated for 5 minutes at 37°C. 2-AG (50 μM), AEA (50 μM), or ethanol (2%
final concentration) was added and incubated for 30 minutes at 37°C to assess MAGL
and FAAH activities, respectively. The reaction was terminated with an equal volume of
cold acetonitrile containing AA-d8 (2.5 μM). Samples were then centrifuged (4oC, 10
minutes; 16,000 x g) and the supernatant (100 μl) transferred to vials with glass inserts
for UPLC-MS/MS analysis of arachidonic acid (AA) as performed in the previous
chapter 2 (Carr et al., 2013; Carr et al., 2014). 2-AG and AEA hydrolysis activities are
expressed as the ratio of peak areas for AA and AA-d8. Background levels of AA in
tissue homogenates (substrate blanks) were also determined and subtracted from
samples incubated with exogenous 2-AG or AEA.
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3.2.8

TCP extraction and analysis
TCP levels were determined in the liver of CPS treated animals from standard

chow diet and high fat diet groups. Liver tissue was weighed (100 mg) and
homogenized in 4:1 (v/v) acetonitrile:0.1% acetic acid in water (2 ml) containing an
internal standard (simazine, 2 nmol). The homogenate was sonicated, kept cold (-20°C,
30 minutes), and then centrifuged (10,500 x g, 20 minutes, 4°C). The clear top layer
was dried under nitrogen. The dried residue was reconstituted in 0.1 M HCl (1 ml),
heated (70°C, 1 hour), and then cooled on ice (5 minutes). Ethyl acetate (2 ml) was
added to the acid hydrolysate and the mixture was vortexed and centrifuged (3,000 x g,
5 minutes). The clear top organic layer was removed and dried under nitrogen. The
dried residue was finally reconstituted in 1:1 (v/v) methanol:water (100 μl) for TCP
analysis by UPLC-MS/MS. 10 μl of the sample was injected onto an Acquity UPLC BEH
C18 column (2.1 x 50 mm, 1.7 μm) equipped with Vanguard pre-column (2.1 x 5 mm,
1.7 μm) and eluted with a blend of water and methanol (95:5) containing 0.1% acetic
acid. The column eluate was directed into a Thermo Quantum Access mass
spectrometer (heated electrospray ionization) at a flow rate of 0.2 ml/minute. Pseudo
single reaction monitoring (SRM) of analytes were: TCP, [M-H]- m/z 195.8>195.8
(quantification SRM) and m/z 197.9>197.9 (confirmation SRM); simazine internal
standard, [M+H]+ m/z 202.0>202.0. TCP was quantified by measuring its peak area and
the peak area of the internal standard then comparing the ratio of peak areas to an
external TCP calibration curve. The limit of quantification for TCP was 0.5 ng/ml (lowest
calibration standard). When exogenous TCP was spiked in the blanks and extracted
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following the above procedure, it was stable under the acid hydrolysis conditions and
was recovered in the ethyl acetate fraction.

3.2.9

Determination of CPS bioactivation by desulfuration assay
The bioactivation capacity of standard chow and high fat fed animals was

determined by desulfuration assay (a measure of how much oxon is produced) using
liver microsomes of vehicle treated animals (Chambers et al., 1989; Forsyth et al.,
1989). Preparation of liver microsomes and the assay for CPS desulfuration were
performed as previously described with modifications (Ma et al., 1994). Briefly, the liver
tissue was weighed and then 250 mg was homogenized in Tris-HCl 50 mM (pH 7.4)
buffer. Tissue homogenates were sonicated for 10 seconds at 30% power and repeated
3 times. The homogenates were then centrifuged (17,000 x g, 15 minutes, 4°C) and the
supernatant (S9 fraction) was collected, and the pellet was discarded. The collected
supernatant was centrifuged (100,000 x g, 1 hour, 4°C) to obtain the microsomal pellet.
The supernatant was discarded then the pellet was covered with glycerol storage buffer
and stored at -80°C until further analysis. To determine desulfuration activity the assay
was performed with microsomes (0.2 μg protein/ml) as previously explained in Chapter
2. The amount of CPS-derived oxon produced in the reaction containing microsomal
protein was expressed as CPO nmol min-1 mg P-1.
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3.2.10

Hepatic CYP450 gene expression analysis
Expression of genes governing hepatic xenobiotic metabolism was examined by

rt-PCR as previously described (Mulligan et al., 2017). Genes governing hepatic
xenobiotic metabolism include Cyp3a11, Cyp1a2, Cyp2b10, and Cyp2c29. These
cytochromes are murine orthologues of the prominent human cytochrome P450
enzymes (Nelson et al., 2004). Total RNA was isolated from the liver samples using an
RNA purification kit (Gene Jet, Thermo Fischer). Briefly, liver (30 mg) homogenates
were prepared in lysis buffer (300 µl) with beta-mercaptoethanol (20 µl). The liquid
phases were separated by centrifugation at high speed (12,000 x g, 15 minutes, 4°C)
and supernatant separated to an RNAase free centrifuge tube and then ethanol (450 µl)
was added. The Gene JET RNA Purification column was used to separate the RNA by
centrifugation at high speed (12,000 x g, 1 minute, 4°C). The column was washed 3
times using wash buffer consisting of guanidine thiocyanate (supplemented with 100%
ethanol) to remove the impurities and then centrifuged at high speed (12,000 x g, 1
minute, 4°C). After that the RNA was eluted using RNAase free water (40 µl), it was
stored at -80°C until further analysis. The concentration and quality of isolated RNA
were determined by using a NanoDrop1000 spectrophotometer. RNA was reversetranscribed into cDNA from 1 μg RNA by using a high-capacity cDNA kit (Verso cDNA
Synthesis Kit; Thermo Fisher). For quantitative analysis of cDNA gene expressions, rtPCR was performed using a 2x Light Cycler 480 with Sybr Green detection (Sybr Select
Master Mix; Thermo Fisher), PCR Reaction with Universal 2X Master Mix and primers,
and beta-actin as the housekeeping gene. Data are expressed as the fold change from
the average of standard diet fed vehicle treated animals.
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3.2.11

Statistical analysis
Statistical analysis for the hydrolysis of 2-AG and AEA assays was performed on

the log10 transformed AA/AA-d8 ratios. The data were analyzed by two-way analysis of
variance (ANOVA) with Tukey's post hoc test utilizing pairwise comparisons (GraphPad
PRISM 7) to determine the potential effects of diet and CPS exposure on the measured
endpoints. All data are expressed as the mean ± SEM. The Student’s t-test was utilized
to determine significant differences in experiments with only two groups. A P-value less
than or equal to 0.05 (P≤0.05) was deemed to be a statistically significant difference
between groups throughout. For rt-PCR data analysis, statistical significance was
determined on the ΔCt values and not the fold change values by utilizing the two-way
ANOVA with Tukey's post hoc test using multiple pairwise comparisons (GraphPad
PRISM 7).

3.3
3.3.1

Results
Effects of acute CPS exposure on physical and biochemical markers of
obesity and metabolic function
Consumption of high fat diet resulted in significant weight gain in both vehicle

(18%) and CPS (12%) treated animals compared to vehicle treated animals that
consumed standard rodent chow (Table 3). In addition to increased weight gain, high fat
fed animals exhibited dyslipidemia with significantly elevated plasma triglycerides by
40% and 33% as well as elevated plasma total cholesterol by 29% and 33% in vehicle
and CPS treated animals, respectively, compared to vehicle treated animals on the
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standard chow diet. The high fat diet induced dyslipidemia was accompanied by a high
fat diet induced increase in hepatic triglyceride content in both vehicle (86%) and CPS
(57%) treated animals compared to their corresponding standard diet control animals
(Table 3). Interestingly, acute administration of CPS also significantly increased plasma
triglyceride levels in animals on the standard chow diet by 39% compared to vehicle
treated animals on the same diet. While consumption of the high fat diet did not
significantly alter fasting blood glucose levels, acute exposure to CPS significantly
decreased fasting blood glucose levels by 12% in both standard and high fat diet fed
animals. Plasma insulin levels were significantly decreased in both vehicle (41%) and
CPS (28%) treated high fat fed animals compared to their corresponding standard diet
controls (Table 3). However, these alterations in fasting plasma insulin did not
significantly alter fasting blood glucose levels.

Table 3.1

Physical and biochemical measurements following CPS exposure.

Mice were fed standard rodent chow or high fat diet for four weeks with acute
administration of CPS (2.0 mg/kg; oral gavage). Data represent the mean ± SEM of
n=6-8 animals/group. *P≤0.05 vs. corresponding diet control; #P≤0.05 vs. vehicle
treated animals on standard chow diet.
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3.3.2

Acute CPS exposure significantly decreases RBC and plasma
cholinesterase activities
Exposure to CPS did not significantly inhibit either brain or skeletal muscle AChE

activities in the standard or high fat fed diet groups (Figure 10A & 10B). There was a
significant CPS mediated decrease in RBC AChE activities in both standard (~39%
inhibition) and high fat fed (~49% inhibition) animals compared to vehicle treated
animals on a standard diet and this inhibition was greater for CPS treated animals
(~59% inhibition) on a high fat compared to vehicle treated animals on a high fat diet
(Figure 10C). However, there was no effect of diet on CPS mediated inhibition of RBC
AChE activity. Acute exposure to CPS significantly decreased plasma ChE activity in
both standard (~50% inhibition) and high fat fed (~63% inhibition) animals compared to
vehicle treated animals on a standard diet (Figure 10D). Interestingly, vehicle treated
animals on a high fat diet had significantly reduced plasma ChE activities (~48%
inhibition) compared to vehicle treated animals on a standard diet indicating a high fat
diet dependent reduction in plasma ChE activity.
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Figure 3.1

Effect of CPS (2 mg/kg) exposure on cholinesterase activity in the brain,
RBC, skeletal muscle, and Plasma.

Effects of CPS exposure on central and peripheral CNS activities in standard chow
(STD) or high fat diet (HFD) fed animals. Twelve hours following CPS exposure, AChE
activities in brain (A), gastrocnemius muscle (B), RBCs (C), or ChE activities in plasma
(D) were measured and normalized to the corresponding protein values. Data are
expressed as mean ± SEM of n=8 animals/group. *P≤0.05 vs. vehicle treated animals
on standard chow diet; #P≤0.05 vs. vehicle treated animals on high fat diet.

3.3.3

Plasma arylesterase activity is not significantly altered following high fat
diet intake or acute CPS exposure
Plasma arylesterase activity was measured to determine if high fat intake may

alter plasma PON activity (Figure 11). High fat feeding or exposure to CPS did not
significantly alter plasma paraoxonase activity. While non-significant, there was a slight
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increase in plasma paraoxonase activity in the CPS treated, high fat fed animals which
was unexpected given high fat diet intake has been reported to decrease plasma

Arylesterase activity (units min-1 ml-1)

paraoxonase activity (Thomàs‐Moyà et al., 2008).

Figure 3.2
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Effect of CPS (2 mg/kg) exposure on plasma arylesterase activity.

Plasma PON activity is not significantly altered in standard chow (STD) or high fat diet
(HFD) fed animals. Following sacrifice, plasma paraoxonase activity was determined
using phenyl acetate as the substrate. Data represent the mean ± SEM of n=8
animals/group.

3.3.4

Hepatic CES activity is more sensitive to CPS inhibition in obese animals
Following exposure to CPS, overall CES activity was examined in plasma, the

liver, and adipose tissue homogenates (Figure 12). Exposure to CPS in animals on the
standard diet significantly decreased hepatic CES activity by ~20% when compared to
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vehicle treated animals on the same diet (Figure 12A). While consumption of the high
fat diet slightly, but not significantly decreased hepatic CES activity, exposure to CPS
significantly decreased hepatic CES activity in high fat fed animals compared to vehicle
treated standard diet animals (~64% inhibition) and vehicle treated high fat diet animals
(~58% inhibition). Additionally, CPS mediated CES inhibition was significantly reduced
in high fat fed animals compared to CPS mediated CES inhibition in animals on the
standard chow diet.
CES activity in adipose was significantly decreased in high fat diet vehicle treated
and high fat diet CPS treated animals compared to standard diet vehicle treated
animals, but the CPS exposure did not indicate any effect on adipose CES activity in
standard diet fed animals when compared to the respective vehicle treated animals
(Figure 12B). However, the plasma CES activity was significantly increased in high fat
diet animals and was significantly increased following the CPS exposure in both
standard and high fat diet fed animals (Figure 12C).
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Effect of CPS (2 mg/kg) exposure on CES activity.

CES activity was determined in the liver (A), adipose (B), and plasma (C) in standard
chow (STD) or high fat diet (HFD) fed animals with CPS exposure. Data represent the
mean ± SEM of n=8 animals/group. *P≤0.05 vs. vehicle treated standard chow fed
animals; #P≤0.05 vs. vehicle treated high fat diet fed animals; &P≤0.05 vs. CPS treated
chow fed animals.

3.3.5

Hepatic AEA hydrolysis is more sensitive to CPS inhibition than hepatic
2-AG hydrolysis
Hepatic MAGL and FAAH activities were determined by the hydrolysis of their

endogenous endocannabinoid substrates 2-AG and AEA, respectively, in liver
homogenates (Figure 13). As observed with hepatic CES activity, AEA hydrolysis was
significantly inhibited in CPS treated animals on the high fat diet compared to vehicle
treated animals on the standard chow (~39% inhibition) and the high fat (~37% inhibition)
diets as well as the CPS treated animals on the standard diet (~35% inhibition) indicating
significant inhibition of FAAH activity in the CPS treated high fat diet animals (Figure 13A).
Thus, both hepatic CES and FAAH activities showed similar patterns of CPS mediated
inhibition. Acute exposure to CPS (2 mg/kg) did not significantly inhibit the hydrolysis of
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2-AG to its degradation product, AA in standard diet or high fat diet fed animals, indicating
CPS did not significantly inhibit MAGL activity (Figure 13B). Interestingly, 2-AG
degradation was increased following CPS exposure in standard chow fed animals
compared to vehicle treated animals on the standard chow diet.
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Effect of CPS (2 mg/kg) exposure on hydrolysis of AEA and 2-AG assay.

Hydrolysis of AEA and 2-AG assay in liver homogenates was determined as an index of
FAAH (A) and MAGL (B) activity inhibited with CPS exposure by analyzing the ratio of
AA/AA-d8 levels in standard chow (STD) or high fat diet (HFD) fed animals. Data
represent the mean ± SEM of n=8 animals/group. Statistical analysis was performed on
log10 transformed values. *P≤0.05 vs. vehicle treated standard chow fed animals;
#P≤0.05 vs. vehicle treated high fat diet fed animals; &P≤0.05 vs. CPS treated standard
chow fed animals.

3.3.6

CPS desulfuration is decreased in high fat fed mouse liver microsomes
Effects of diet on CPS metabolism were explored to determine if alterations in

hepatic desulfuration or detoxication to the metabolite TCP may mediate the currently
observed inhibition of hepatic CES and FAAH activities. Interestingly, desulfuration of
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CPS was significantly decreased by 41% in the livers of animals on the high fat diet
compared to animals on the standard chow diet (Figure 14A). Hepatic levels of TCP
were also slightly lower in the high fat fed animals compared to the standard chow fed
animals (Figure 14B). However, this decrease was not statistically significant.
Therefore, the currently observed inhibition of hepatic CES and FAAH in the high fat fed
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group does not appear to be due to increased CPO generation via desulfuration.
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Bioactivation of CPS by desulfuration in hepatic microsomes and
measurement of TCP metabolite in the liver.

CPS desulfuration (A) and dearylation (B) was determined as an index of bioactivation
and degradation in standard chow (STD) or high fat diet (HFD) fed animals. Data
represent the mean ± SEM of n = 6 animals/group. *P≤0.05 vs. vehicle treated standard
chow fed animals.
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3.3.7

High fat diet decreases hepatic expression of cytochrome P450 enzymes
Hepatic expression of Cyp1a2, Cyp2b10, Cyp3a11, and Cyp2c29 was

determined to examine potential alterations in the expression of murine P450 isoforms
which are analogous to major human and rat P450 isoforms that have been implicated
in CPS metabolism (Tang et al., 2001). Overall, expression of each of the four isoforms
was significantly decreased in vehicle treated, high fat fed animals with decreases to 0.6
± 0.05, 0.04 ± 0.02, 0.2 ± 0.03, and 0.4 ± 0.1 fold vs vehicle treated, standard chow fed
animals for Cyp1a2, Cyp2b10, Cyp3a11, and Cyp2c29, respectively (Figure 15).
Additionally, there was only one isoform which was induced following CPS exposure.
Exposure to CPS resulted in significant upregulation of Cyp1a2 in both standard chow
and high fat diet fed animals compared to their corresponding vehicle treated animals.
Thus, the overall inhibitory effect of high fat diet intake on the expression of these P450
isoforms may mediate, at least in part, the observed decrease in CPS desulfuration
observed in the high fat fed animals.
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Effect of high fat diet and CPS (2 mg/kg) exposure on hepatic CYP450
gene expressions.

Hepatic CYP450 gene expression standard chow (STD) or high fat diet (HFD) fed
animals. Data are expressed as the fold change from STD, vehicle treated controls and
represent the mean ± SEM of n = 4-6 animals/group. *P≤0.05 vs. STD vehicle treated
animals; #P≤0.05 vs. HFD, vehicle treated animals.

3.4

Discussion
There is a significant lack of animal studies that have examined the effects of

CPS exposure on both traditional cholinergic targets, AChE, and noncholinergic targets,
CES and the endocannabinoid system, in obese animals where metabolic dysfunction
existed prior to CPS exposure. This is of great importance given that approximately
39.8% of the U.S. adult population is classified as being obese (Hales et al., 2020).
Given the prevalence of obesity, it is vital to determine if obesity and the accompanying
metabolic dysfunction alters systemic toxicities of CPS and other potentially hazardous
pesticides. Based on our in vitro studies in Chapter 2, steatotic conditions in primary
hepatocytes and hepatoma cells altered the CPS toxicities on noncholinergic targets
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when exposed to CPS. Therefore, the goal of the current study was to determine the
effects of being obese or overweight on the cholinergic and noncholinergic targets
following acute exposure to CPS. Classical cholinergic endpoints included effects on
CNS AChE activity in the whole brain, skeletal muscle AChE activity in gastrocnemius
muscle, RBC AChE activity, and plasma ChE activity. Noncholinergic endpoints
included effects on key hepatic serine hydrolases including CES, MAGL, and FAAH,
which have vital roles in xenobiotic metabolism as well as hepatic lipid metabolism.
Exposure to OP pesticides has been linked to metabolic abnormalities, such as
hyperglycemia and hypertriglyceridemia, which are often linked with obesity and type 2
diabetes (Slotkin et al., 2005). Previous studies determined that acute exposure to CPS
(50 mg/kg; subcutaneous injection) induced hyperglycemia and hypertriglyceridemia in
overnight fasted rats (Acker et al., 2012). Hyperglycemia following CPS exposure in rats
at concentrations that significantly inhibited AChE in the CNS has been associated with
hypercorticosteronemia and subsequently increased activities of the hepatic
gluconeogenic enzymes tyrosine aminotransferase and glucose-6-phosphatase (Acker
et al., 2012). Our current results indicate acute exposure to CPS (2.0 mg/kg via oral
gavage) produces hypoglycemia in both standard chow and high fat fed mice. The
current data indicate a comparable pattern to our previous study which demonstrated a
decrease in fasting blood glucose in high fat fed mice following subacute exposure to
CPS (Howell et al., 2018). CNS AChE activity was not significantly inhibited in this
current study, which may explain the lack of CPS induced hyperglycemia given that
ACh receptors in the paraventricular nucleus (PVN) of the hypothalamus have been
shown to increase hypothalamic corticotrophin releasing factor and elevate circulating
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adrenocorticotropic hormone which indicates classical activation of the hypothalamicpituitary-adrenal (HPA) axis (Ohmori et al., 1995; Smallridge et al., 1991).
The primary neurotoxic properties of OP pesticides following acute exposures
are governed by their ability to inhibit AChE, leading to excessive accumulation of ACh
in the synapses. The AChE activities in CNS and skeletal muscle were not significantly
inhibited in the current study following acute CPS (2.0 mg/ kg) exposure. The current
results were anticipated given data demonstrating acute exposure to CPS (12.5 mg/kg)
via gavage did not significantly inhibit CNS AChE and that the benchmark dose for CNS
AChE inhibition following acute CPS exposure is 5.9 mg/kg/day (Cometa et al., 2007;
Zhao et al., 2006). In the current study, we observed inhibitory effects of CPS on RBC
AChE activity which were comparable to those previously observed following sub-acute
CPS (2.0 mg/kg, oral gavage, 10 days) exposure in animals receiving the same dietary
regimen and did not indicate increased inhibition following repeated exposures (Howell
et al., 2018). As was expected, RBC AChE and plasma ChE activities were more
sensitive to CPS exposure mediated inhibition than CNS AChE (Zheng et al., 2000).
The plasma ChE activity in vehicle treated high fat fed animals was significantly
lower than that observed in vehicle treated standard chow fed animals. The plasma ChE
activity following high fat diet intake has not been previously reported. CNS AChE
activities following long term high fat diet intake in rats have been reported with
conflicting reports. High sugar, high fat diet consumption for six months in male and
female rats has been reported to decrease CNS AChE activity (Kaizer et al., 2004).
However, Kosari et al. (2012) demonstrated there is no effect on CNS AChE activity
following high fat diet intake for twelve weeks in male rats and additionally, in the
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present study, CNS AChE activity was not inhibited following high fat diet intake for four
weeks in male C57BL/6J mice (Kosari et al., 2012). Given the disagreement about the
effects of high fat diet intake on CNS AChE activities, future studies should be designed
to more accurately determine the effects of dietary manipulations on both central and
peripheral AChE activities.
The noncholinergic targets of OPs are the metabolic serine hydrolase family of
enzymes, such as CES, FAAH, and MAGL. The CES family of enzymes are expressed
significantly in different tissues and play an established role in xenobiotic detoxication
(Potter et al., 2006; Ross et al., 2010; Satoh et al., 1998; Satoh et al., 2002). CES are
also involved in lipid metabolism. As previously mentioned, studies have demonstrated
that both CES1 and murine Ces1d are involved in the mobilization of intracellular
triglycerides in hepatocytes for export via VLDL with variable results on hepatic lipid
accumulation (Bahitham et al., 2016; Erickson et al., 2013; Gilham et al., 2003; Lehner
et al., 1999; Lian et al., 2018; Quiroga et al., 2012; Ruby et al., 2017). In the present
study, our results do not differentiate between the individual CES isoforms that are
inhibited by CPO. However, they do demonstrate that there is a significant interaction
between high fat diet and CPS through potentiated CPS mediated inhibition of overall
hepatic CES activity in obese animals compared to that in lean animals. These results
were comparable to previous studies from our lab where repeated CPS (2 mg/kg/day)
administration for ten days decreased hepatic and adipose CES activities (Howell et al.,
2018). As opposed to the liver, CES activities in the adipose were significantly
decreased following high fat diet intake but were unaffected by CPS exposure.
However, plasma CES activity was significantly increased following CPS exposure in
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both lean and obese animals and no effect with diet (Figure 12C). Thus, these data
indicate the interaction between diet and CPS exposure on CES activity were primarily
restricted to the liver. CPS exposure had a more pronounced effect on plasma CES
activity as the activity was increased following CPS exposure.
The CPS (2 mg/kg) mediated inhibition of hepatic CES and FAAH activities and
absence of inhibition of MAGL activity is most likely due to differential intrinsic
sensitivities of the serine hydrolases to inactivation by the reactive metabolite CPO. The
rank order of sensitivity for each enzyme toward CPO is CES > FAAH > MAGL, as
previously reported (Casida et al., 2004; Casida et al., 2005; Quistad et al., 2006).
Additionally, our in vitro data in rat hepatocytes also demonstrated a more pronounced
CPS mediated suppression of CES and FAAH activities compared to that of MAGL
activity. Inhibition of CES activity under steatotic conditions was more pronounced
following exposure to CPS compared to normal conditions, which further reinforces our
in vivo findings in the current study.
In the present study, in vivo data demonstrated significant interactions between
diet and CPS exposure resulting in greater CPS dependent inhibition of hepatic CES
and FAAH activities in high fat fed mice than those in standard chow fed mice. This
effect does not appear to be caused by increased bioactivation of CPS to CPO, which
would have been indicated by increased rates of CPO formation in livers of high fat fed
mice relative to those of standard chow fed mice, instead, the opposite was found
(Figure 14A). A potential mechanism for this particular result may be due to high fat diet
mediated downregulation in the expression of CYP isoforms that bioactivate CPS to
CPO (Figure 15). The differential inhibition of serine hydrolase activities following
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exposure to CPS might be due to the steatotic state of livers following high fat feeding.
Chambers et al. (1993) demonstrated CPS is highly lipophilic and proposed the
hypothesis that CPS effects may persist due to the formation of storage depots in lipid
rich tissues (Chambers et al., 1993). High fat feeding for four weeks produced an
increase in intracellular neutral lipid accumulation, as indicated by increased triglyceride
content in the liver. The possibility arises that CPS is sequestered into intracellular lipid
droplets where it leaks out over time. A recognized limitation of the current study is that
it does not address time dependent changes in enzyme inhibition following CPS
exposure, such as examining whether hepatic steatosis alters the time course of
inhibition of CES and FAAH.

3.5

Conclusion
In summary, the present study revealed a significant interaction between high fat

diet and CPS exposure. In this study, this interaction resulted in a difference in the
inhibitory effects of acute exposure to CPS on hepatic CES activity and on hepatic
FAAH activity in animals fed with high fat diet compared to a standard chow diet. These
data indicate that obesity and accompanying pathological alterations, such as hepatic
steatosis, may potentiate CPS mediated inhibition of the serine hydrolases that play a
role in hepatic lipid metabolism. Thus, obesity might be an important risk factor for
hepatic noncholinergic CPS toxicity. In addition to the previously mentioned
toxicokinetic studies, future studies will determine the specific isoforms of CES in the
liver that are inhibited following acute CPS exposure in high fat fed animals, and
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whether the degree of obesity and type 2 diabetes progression exacerbates CPS
mediated cholinergic and noncholinergic toxicity.
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CHAPTER IV
DETERMINE THE TOXICOKINETICS AND TOXICODYNAMICS OF CHLORPYRIFOS
(CPS) IN STANDARD DIET AND HIGH FAT DIET FED ANIMALS.
4.1

Introduction
Organophosphates (OPs) have been widely used as pesticides in agriculture and

household settings. CPS is the most widely used phosphorothioate insecticide for
agriculture purposes (Atwood et al., 2017). CPS is one of the most lipophilic OPs and
previous studies have indicated this compound may be stored temporarily in fat and
slowly released over a period of time. It is anticipated that a slow release may delay or
prolong toxic effects mediated by CPS exposure (Chambers et al., 1993).
Phosphorothioate insecticides, like CPS, need to undergo bioactivation via a
desulfuration reaction catalyzed by cytochrome P450 (CYP450) mediated oxidation
from thions (P=S) to oxons (P=O) to be more potent inhibitors of acetylcholinesterase
(AChE) (Testai et al., 2010). The primary target of acute neurotoxicity following
exposure to CPS is the inhibition of AChE. Inhibition of AChE leads to an increase in the
neurotransmitter acetylcholine levels in the nerve synapse leading to overstimulation in
both the central and peripheral nervous systems (Smith et al., 1967) The CYP450
enzymes are also directly responsible for the detoxication of CPS by catalyzing the
dearylation reaction to its inactive metabolite, 3,5,6- trichloro-2-pyridinol (TCP) (Buratti
et al., 2003; Tang et al., 2001). In addition to CYP450 mediated detoxication,
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chlorpyrifos oxon (CPO) can also be detoxified to TCP via hydrolysis by paraoxonase-1
(PON-1) and carboxylesterases (CES) (Chambers et al., 1990; Crow et al., 2010).
Along with the primary cholinergic toxicity produced by inhibition of AChE in the central
and peripheral nervous systems, the other noncholinergic endpoints of OP toxicity are
inhibition of metabolic serine hydrolases monoacylglycerol lipase (MAGL), and fatty acid
amide hydrolase (FAAH) and CES (Casida et al., 2004; Ross et al., 2014).
Concerning potential health effects, studies have shown that exposure to CPS
can cause hypertriglyceridemia leads to abnormal lipid metabolism in the liver with an
increase in neutral lipid accumulation and de novo lipogenesis with a decrease in
triglyceride secretion (Howell et al., 2016; Slotkin et al., 2005). Also, exposure to CPS is
shown to increase body weights and cause sex-specific hypercholesterolemia in male
rats when fed with high fat diet (Lassiter et al., 2008). These effects on lipid metabolism
and weight are significant in that it may potentially contribute to the increasing
prevalence of metabolic diseases including obesity and nonalcoholic fatty liver disease
(NAFLD) (Montgomery et al., 2008). The metabolic complications of obesity include
ectopic lipid accumulation and hepatic steatosis (Singla et al., 2010). Also, previous
studies from our lab indicated that consumption of a high fat diet for four weeks induced
hepatic steatosis along with increased hepatic triglyceride content and body weights
(Howell et al., 2018). CPS is a lipophilic compound that primarily accumulates in the
adipose tissue compared to other tissue compartments in rats following oral dosing
(Bakke et al., 1976). As previously discussed, the calculated tissue distribution of CPS,
based on tissue:blood partition coefficient (logp) values, was higher in the adipose
tissue compared to other tissue compartments (Poulin et al., 1995; Timchalk et al.,
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2002). A recent study demonstrated that some OP compounds with increased
lipophilicity, such as CPS, have a persistent toxic effect in obese patients demonstrated
by their longer duration of critical care needs compared to patients of normal weight
(Lee et al., 2014).
Pharmacokinetic studies performed by Suemizu et al. (2014) revealed a 30
mg/kg of CPS (via oral route) in normal TK-Nog mice produced measurable levels of
CPS at 2 hours and detectable CPS levels up to 7 hours post-dose in plasma (Suemizu
et al., 2014). Studies in CD-1 mice following CPS (25 mg/kg, via oral gavage) exposure
demonstrated that mild functional signs of OP toxicity, mainly salivation, lacrimation,
urination, and defecation (SLUD), were observed two hours post dosing (Cometa et al.,
2007). The peak inhibition of AChE in the brain (20%) occurred at 6 hours post dosing,
and serum cholinesterase activity remained significantly inhibited (75%) up to 72 hours
compared to control animals (Cometa et al., 2007).
Our previous study noted a significant decrease in expression of CYP450
(Cyp2a10, Cyp3a11, Cyp2c29) and a decrease in the desulfuration activity of CPS to
CPO in high fat fed mice (Howell et al., 2018). Reduced CYP450 levels may decrease
the bioactivation of CPS to its active metabolite, CPO, but may also decrease
detoxication to TCP. Based on the current data, the possibility arises that CPS can
accumulate in high fat diet fed animals and alter the toxicokinetics of the parent
compound CPS and its detoxified metabolite, TCP, which may produce prolonged toxic
effects. Currently, there are no animal studies exploring the effects of high fat diet
induced obesity on the bioavailability of CPS and its metabolism to the main
detoxication metabolite, TCP. Thus, the present study was designed to determine the
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effect of high fat diet on the bioaccumulation of CPS and its detoxified metabolite TCP
in the liver and plasma.

4.2
4.2.1

Experimental Methods
Chemicals
CPS (≥99% purity) was purchased from Sigma-Aldrich (St. Louis, MO ), and

stock solutions were prepared in corn oil for animal dosing and acetonitrile (Optima®
grade) from Fisher chemical (Thermo Fisher Scientific, Waltham, MA) for quantitative
analysis of CPS in tissues and plasma. CPS diethyl-d10 (99% purity) was purchased
from Cambridge Isotope Labs (Cambridge Isotope Labs, MA). 2-AG (≥95% purity), AEA
(≥98% purity), and arachidonic acid-d8 (AA-d8, ≥96% purity) were purchased from
Cayman Chemicals (Ann Arbor, MI). The solid phase extraction (SPE) column
cartridges (HyperSep Retain PEP, 60 mg) for analyte separation were purchased from
Thermo Fischer Scientific (Waltham, MA). Solvents used for CPS and TCP analysis by
ultra-performance liquid chromatography – tandem mass spectrometry (UPLC-MS/MS)
including methanol (Optima® LC-MS grade), water (Optima® LC-MS grade), ethyl
acetate (Optima® LC-MS grade ), and acetic acid (Optima® LC-MS grade) were
purchased from Fisher Chemical (Thermo Fisher Scientific, Waltham, MA).

4.2.2

Animal care
Male C57BL/6J (n=64) mice were purchased from Jackson Laboratories. Upon

arrival, animals were selected randomly, and group housed at Mississippi State
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University (MSU) College of Veterinary Medicine in Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC) approved animal
facility and allowed access to food and water ad libitum unless otherwise stated. All
animal protocols were approved by the MSU Institutional Animal Care and Use
Committee (IACUC) prior to implementation.

4.2.3

Dosing and sample collection
Male C57BL/6J mice (4 weeks of age) were grouped (n=8/group) and fed for 4

weeks with standard rodent chow diet (Teklad 18% protein rodent diet) or high-fat diet
(60% kcal from lard; ResearchDiets) to induce obesity and alterations in systemic lipid
metabolism (Table 4). Following 4 weeks of diet intake (8 weeks of age), animals were
dosed with a single dose of CPS (25 mg/kg) or vehicle (corn oil; 1 ml/kg). The current
dose utilized in this study was based on a previous study where CPS (25 mg/kg) in CD1 mice produced mild or no signs of toxicity, as indicated by SLUD (Cometa et al.,
2007). While the current dose is 10 fold higher than our previous study in Chapter 3, the
current dose was chosen in order to recover measurable CPS levels to determine the
effect of high fat diet on bioaccumulation of the parent compound and its detoxified
metabolite (Cometa et al., 2007; Suemizu et al., 2014). Food was removed 3 hours prior
to dosing and food was then replaced 2 hours post dosing. The animals sacrificed at 0
hours were dosed with corn oil then immediately sacrificed and considered the vehicle
group. The animals dosed with CPS (25 mg/kg) were sacrificed after 3, 6, and 12 hours.
Animals were euthanized by CO2 asphyxiation, then blood was drawn by cardiac
puncture and collected into sodium heparin coated vacutainers. RBC fraction and
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plasma were separated by centrifugation of whole blood (1000 x g, 10 minutes, 4oC)
and stored at -80oC. The liver and brain tissues were collected and snap frozen at -80oC
until further analysis.

Table 4.1

Experimental design of time dependent effects of CPS exposure on
cholinergic and noncholinergic targets.

Time-dependent effects of CPS on cholinergic and noncholinergic targets.
4.2.4

Sample preparation for CPS extractions
Liver (100 mg) was homogenized with a Powergen-125 homogenizer in 4:1 v/v

acetonitrile:water (1 ml) and vortexed for 2 minutes to stop the enzymatic reactions.
CPS internal standard CPS diethyl-d10 (200 ng/ml in acetonitrile) was then added to the
samples. Samples were then placed in the freezer and incubated at -20oC for 30
minutes and then centrifuged (20 minutes at 10,600 x g, 4oC). The supernatant was
separated into clean glass tubes and dried under a nitrogen stream. The dried residue
was resuspended in (95:5) acetonitrile:water (500 µl) and transferred to the SPE
cartridge. The SPE column cartridges were equilibrated with methanol (5 ml), then
acetonitrile (5 ml) and water (5 ml) prior to sample addition. The samples were added to
the equilibrated SPE cartridge and incubated for 5 minutes then the column was
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washed with 95:5 v/v water:acetonitrile (5 ml). The sample was eluted with 10 ml of
acetonitrile and collected into a fresh glass tube. The eluted sample was evaporated
under a gentle stream of nitrogen until dry. The dry residue was resuspended in 100 µl
methanol:water (1:1) and filtered through a 0.2 μm spin filter then subjected to analysis
by UPLC-MS/MS. The quantitation of analytes in the mass spectrometry was done by
utilizing Xcalibur software (Kopjar et al., 2018).
To determine plasma CPS levels, CPS was extracted from plasma as described
above with minor modifications. Briefly, CPS was extracted from the plasma (50 µl) and
CPS internal standard CPS diethyl-d10 (200 ng/ml) in acetonitrile was added to the
samples and vortexed for 30 seconds. Then 200 μl of acetonitrile:water (2:1) was added
to each sample to stop the enzymatic reactions and samples were incubated at -20°C
for 30 minutes and then centrifuged (10,600 x g for 20 minutes, 40C). The CPS
calibration curve was prepared with a range of 3 ng/ml to 300 ng/ml by spiking the CPS
in target tissues and followed the above described process. Samples were subjected to
analysis by UPLC-MS/MS and quantitation was done by utilizing Xcalibur software as
described below (Kopjar et al., 2018).

4.2.5

UPLC-MS/MS analysis for CPS
For CPS analysis by UPLC-MS/MS, 10 µl of the sample was injected onto a

Waters Acquity UPLC BEH C-18 column (2.1 × 50 mm, 1.7 μm) equipped with Waters
VanGuard pre-column (2.1 × 5 mm, 1.7 μm) to protect the column. Samples were
chromatographed with a two-component mobile phase consisting of the following,
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component A: (5:95) methanol:water containing 0.1% acetic acid and component B
100% methanol containing 0.1% acetic acid. The compound was eluted by utilizing the
following gradient at a flow of 0.2 ml/minute and the mobile phase gradient elution
method had the following volume ratios: The method started with 85:15 v/v components
A:B held for the first 2 minutes, inclined gradient up to 20:80 v/v components A:B at 4
minutes, incline further to 15:85 v/v components A:B at 8 minutes, reverting to the
original conditions of 99:1 v/v components A:B starting at 16 minutes until method
completion. The column temperature was set at 40⁰C to decrease solvent viscosity and
to enhance elution rates through the UPLC column. The eluate was directed into a
Thermo Quantum Access Max mass spectrometer (heated electrospray ionization).
Pseudo selected reaction monitoring (SRM) of analytes were: CPS, [M+H]−m/z 350.5 >
350.5 (quantification SRM) and m/z 357.5 > 357.9 (confirmation SRM); CPS diethyl-d10
internal standard, [M+H]+m/z 360.6 > 360.6. CPS was quantified by measuring its peak
area and the peak area of the internal standard then comparing the ratio of peak areas
to an external CPS calibration curve. The limit of quantification for CPS was 3 ng/ml
(lowest calibration standard). The accuracy of the proposed UPLC method was
estimated by recovery study of standard addition method by using three known
concentrations of CPS (3, 30, 100ng/ml) and analyzed by the method, the recovery
percentage of CPS with the UPLC method was nearly 60% in plasma and tissues.
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4.2.6

TCP metabolite extractions
The measurement of TCP levels in the CPS treated mouse liver and plasma

were determined as the product of the detoxication process. Briefly, liver tissue from
vehicle or CPS treated animals were weighed (approximately 100 mg) and mechanically
homogenized in 1 ml of (4:1) acetonitrile: water containing 0.1% acetic acid and
simazine as internal standard (200 µM, final concentration). The plasma (50 µl) sample
was extracted by adding 250 µl of (4:1) acetonitrile: water containing 0.1% acetic acid
and internal standard (200 µM, final concentration). The tissue homogenate or plasma
samples were sonicated and frozen (-20oC for 30 minutes in order to separate the
proteins by precipitation and centrifuged (10,500 x g for 20 minutes at 4 oC). The clear
top layer was transferred and dried under a steady flow of nitrogen. The dried residue
was resuspended in HCl (0.1 M, final concentration) with water (1 ml) and incubated
(70oC for 1 hour) then cooled on ice (5 minutes). Ethyl acetate (2 ml) was added to
recover the TCP metabolites after acid hydrolysis. The solution was vortexed and then
centrifuged (3000 x g for 5 minutes, 4oC). The organic layer was separated and dried
under a gentle stream of nitrogen. The dried residue was dissolved in 100 µl of (1:1)
methanol:water and subjected to analysis of TCP by UPLC-MS/MS (Howell et al., 2018;
Ross et al., 2007).

4.2.7

TCP analysis by UPLC-MS/MS
The extracted sample (10 µl) was injected onto an Acquity UPLC BEH C18

column (2.1 × 50 mm, 1.7 μm) equipped with Vanguard pre-column (2.1 × 5 mm, 1.7
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μm) and chromatography of analytes was performed as described in Chapter 3. TCP
levels were quantified as described above. The limit of quantification for TCP was 0.5
ng/ml and the recovery percentage of TCP with the proposed UPLC method was nearly
70% in plasma and tissues.

4.2.8

MAGL and FAAH activity assays
The hydrolysis of the endogenous endocannabinoids, 2-AG and AEA, was

utilized to determine if CPS exposure alters the activities of the serine hydrolases
primarily responsible for their degradation, MAGL, and FAAH, respectively, as
described in the previous Chapter 3 (Carr et al., 2013; Carr et al., 2014). Briefly, protein
levels in tissue homogenates were determined by the Bradford protein assay. The
tissue homogenates were diluted to the final protein concentration of 0.5 mg/ml in TrisHCl (50 mM, pH 7.4) and pre-incubated for 5 minutes at 37°C. 2-AG (50 μM; Cayman
Chemicals), AEA (50 μM; Cayman Chemicals), or ethanol (2% final concentration) as
blank was added and incubated for 30 minutes at 37°C to assess MAGL and FAAH
activities, respectively. The reaction was terminated with an equal volume of cold
acetonitrile containing AA-d8 (2.5 μM; Cayman Chemicals). Samples were then
centrifuged (10 minutes; 16,000 x g, 4oC) and the supernatant collected for UPLCMS/MS analysis of AA, as performed in Chapter 2 (Carr et al., 2013; Carr et al., 2014).
2-AG and AEA hydrolysis activities were expressed as the ratio of peak areas for AA
and AA-d8. Background levels of AA in tissue homogenates (substrate blanks) were
also determined and subtracted from samples incubated with 2-AG or AEA.
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4.2.9

CES continuous assay
CES continuous assay was utilized to measure the activities in both the tissue

homogenates and plasma (Crow et al., 2008; Ross et al., 2007). Briefly, hydrolysis
reactions were performed with tissue homogenates or plasma diluted to 100 μg
protein/ml and para-nitrophenyl valerate (Sigma-Aldrich) as the substrate added at a
final concentration of 500 μM. After a 5 minutes pre-incubation at 37°C, the reaction
was initiated by the addition of tissue homogenate in 50 mM Tris–HCl buffer (pH 7.4).
The reaction was measured spectrophotometrically at 405 nm over 5 minutes to
determine the rate of formation for para-nitrophenol, the chromogen, using an extinction
coefficient of 13 cm−1 mM−1. Data were normalized to enzyme activity units and
expressed as µmol min-1 mg P-1 (Ross et al., 2007).

4.2.10

Cholinesterase and arylesterase activity assays
AChE activity assay was determined in brain and RBC samples, ChE activity

assay was determined in plasma samples. The assays were determined by a
modification of the Ellman method and were performed the assay as briefly explained in
chapter 3 (Chambers et al., 1989; Ellman et al., 1961). Data were normalized to enzyme
activity and expressed as nmol/min/mg P.
PON-1 activity was determined in plasma by using phenylacetate as a substrate
(Davis et al., 2009; Gan et al., 1991). The assay was performed as briefly explained in
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chapter 3. The data are expressed in units/min/ml by subtracting averages of the EDTA
blanks from the calcium buffer-containing wells.

4.2.11

Statistical Analysis
All data are expressed as the mean ± standard error of the mean (SEM). The

statistical analysis for the data from hydrolysis of 2-AG or AEA assay were performed
on the transformed (log10 transformation) AA/AA-d8 ratios. Data were analyzed by twoway analysis of variance (ANOVA) with a Tukey's post hoc test utilizing pairwise
comparisons (Graphpad PRISM v7) to determine the potential effects of diet and CPS
exposure on the measured endpoints. The area under the curve (AUC) analysis for the
CPS and TCP levels in plasma or the liver was computed by the trapezoidal method
utilizing Graphpad PRISM v7 software. A P-value less than or equal to 0.05 (P≤ 0.05)
was deemed to be a statistically significant difference between groups throughout.

4.3
4.3.1

Results
Acute CPS (25 mg/kg) exposure significantly decreases RBC AChE and
plasma cholinesterase activities
Exposure to CPS (25 mg/kg) did not produce any significant inhibition of brain

AChE activity in standard and high fat diet fed animals. The activity of brain AChE was
decreased by nearly 20 percent after 3 hours in standard diet fed animals and after 6
hours in high fat diet fed animals (Figure 16A). RBC AChE activity was significantly
decreased following exposure to CPS (25 mg/kg) in both standard diet fed and obese
animals (Figure 16B). In high fat diet fed animals, peak inhibition (60%) was observed
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after 6 hours, whereas peak inhibition occurred at 3 hours in standard diet fed animals.
RBC AChE activity in standard diet fed animals decreased by nearly 71% after 3 hours,
61% after 6 hours, and 64% after 12 hours. In high fat diet fed animals RBC AChE
activity was decreased after 3 hours by nearly 47%, 59% after 6 hours, and 50% after
12 hours. The peak inhibition of RBC AChE activity was observed after 3 hours in
standard diet fed animals and after 6 hours in high fat diet animals (Figure 16B). Plasma
ChE activity was significantly inhibited by 70% after 3 hours and remained significantly
inhibited 70% after 12 hours in both standard and high fat diet fed animals (Figure 16C).

Figure 4.1

Effect of CPS (25 mg/kg) exposure on cholinesterase activity in the brain,
RBC, and Plasma.

Effects of CPS exposure on the central nervous system AChE and peripheral ChE
activities in the brain (A), RBCs (B), or plasma (C) were measured and normalized to
the corresponding protein values. Data are expressed as mean ± SEM of n= 5-6
animals/group. *P≤0.05 vs. 0 hours STD, &P≤0.05 vs. 0 hours HFD, #P≤0.05 to the
corresponding STD time point.
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4.3.2

Plasma arylesterase activity was significantly altered in standard diet fed
animals
Plasma arylesterase activity was measured to determine potential alterations of

plasma PON-1 activity. Plasma PON-1 activity was significantly decreased by 40% in
standard diet fed animals after 3 hours of CPS exposure and this inhibition persisted
through the 6 and 12-hour time points (Figure 17). High fat fed animals did not show
any significant alterations of plasma PON-1 activities with CPS exposure. Thus, the
current data indicate that the CPS exposure mediated alterations on plasma PON-1

Arylesterase activity (units min-1 ml-1)

activity were less sensitive when compared to standard diet fed animals.
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Figure 4.2

Effect of CPS (25 mg/kg) exposure on plasma arylesterase activity.

Plasma arylesterase activity was analyzed to determine the effect of CPS exposure on
the PON-1 activity in plasma using phenyl acetate as the substrate in standard chow
(STD) or high fat diet (HFD) fed animals. Data represent the mean ± SEM of n=6
animals/group. *P≤0.05 vs. 0 hours STD, #P≤0.05 to the corresponding STD time point.
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4.3.3

Effect of high fat diet on CPS inhibition of CES activity in plasma and
liver
Exposure to CPS (25 mg/kg) significantly decreased plasma CES activity after 3

hours by 92% and 83% in standard diet and high fat diet fed animals, respectively
(Figure 18A). The high fat diet fed animals showed 50% inhibition in the CES activity
after 12 hours in plasma which was a significantly decreased degree of inhibition
compared to the standard diet fed animals at 12 hours. Hepatic CES activity was
significantly decreased following CPS exposure after 3 hours by 60% and 86% in
standard diet and high fat diet fed animals, respectively (Figure 18B). The high fat diet
fed animals at 3 hours showed slightly increased inhibition, but this was not significant
compared to standard diet fed animals at 3 hours. Unlike plasma CES activities, there
was no recovery of hepatic CES activities in the high fat fed animals at 12 hours
compared to the standard diet fed animals.
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Effect of CPS (25 mg/kg) exposure on CES activity.

CES activity was determined the effect of CPS exposure in plasma (A) and liver (B) of
standard chow (STD) or high fat diet (HFD) fed animals. Data represent the mean ±
SEM of n = 5-6 animals/group. *P≤0.05 vs. 0 hours STD, &P≤0.05 vs. 0 hours HFD,
#P≤0.05 to the corresponding STD time point.

4.3.4

Effect of high fat diet on CPS exposure mediated inhibition of FAAH and
MAGL activities
Hepatic MAGL and FAAH activities were determined by the hydrolysis of their

endogenous endocannabinoid substrates, 2-AG and AEA, respectively, in liver
homogenates (Figure 19). Exposure to CPS (25 mg/kg) significantly decreased FAAH
activity by 44% after 3 hours in standard diet fed animals and 51% in high fat diet fed
animals (Figure 19A). The peak inhibition of FAAH activity was observed after 6 hours
in standard diet fed animals (60%) and high fat diet fed animals (68%). The high fat diet
did not produce any significant effect on CPS mediated inhibition of FAAH activity.
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Exposure to CPS (25 mg/kg) did not produce any significant differences in MAGL
activity, as indicated by 2-AG hydrolysis, within the respective diet groups (Figure 19B).
However, standard diet fed animals had a slight decrease in MAGL activity by 12% from
3 to 12 hours. Basal MAGL activity in high fat diet fed animals was significantly
decreased compared to standard diet fed animals basal MAGL activity.
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Effect of CPS (25 mg/kg) exposure on hydrolysis of AEA and 2-AG assay.

Hydrolysis of AEA and 2-AG assays were used to determine the effect of CPS exposure
inhibition of hepatic FAAH (A) and MAGL (B) activities in homogenates of standard
chow (STD) or high fat diet (HFD) fed animals. Data represent the mean ± SEM of n =
5-6 animals/group. Statistical analysis was performed on log10 transformed values.
*P≤0.05 vs. 0 hours STD, &P≤0.05 vs. 0 hours HFD, #P≤0.05 to the corresponding STD
time point.

4.3.5

Effect of high fat diet on CPS levels over time
CPS levels were determined in plasma and the liver to assess the effect of high

fat diet on bioavailability. Plasma CPS levels were significantly decreased after 6 hours
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by 58% and 45% in the standard diet and high fat diet animals, respectively, compared
to levels after 3 hours (Figure 20A). The high fat diet did not produce any significant
effect on overall CPS levels in plasma, as indicated by the AUC measurements (Figure
20C, Table 5). Hepatic CPS levels were significantly decreased after 12 hours by 68%
in both standard diet and high fat diet fed animals compared to CPS levels after 3 hours
(Figure 20B). The high fat diet did not significantly alter overall hepatic CPS levels as
indicated by AUC measurements (Figure 20D; Table 5). The recovery percentage of
CPS with the proposed UPLC method in the current study was determined in the liver
and plasma was 62% and 61% respectively (Table 6).
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Measurement of CPS levels in the liver and plasma.

Plasma (A) and hepatic (B) CPS levels were determined and area under the curve
(AUC) values were determined for the overall availability of CPS in plasma (C) and the
liver (D). Data represent the mean ± SEM of n = 5-6 animals/group. *P≤0.05 vs. 3 hours
STD. &P≤0.05 vs. 3 hours HFD.
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4.3.6

Effect of high fat diet on TCP levels over time
TCP is the major detoxication metabolite of CPS. Thus, TCP levels were

determined in plasma and the liver for the quantification of TCP. Plasma TCP levels
were significantly decreased after 12 hours by 88% and 90% in the standard diet and
high fat diet animals, respectively, compared to the peak levels at 3 hours (Figure 21A).
The high fat diet did not produce any significant effect on overall plasma TCP levels
based on AUC measurements (Figure 21C). There was a significant decrease in
hepatic TCP levels when compared to 3 hours by 55% after 6 hours and 90% after 12
hours in the high fat diet fed animals (Figure 21B). In the standard diet fed animals
when compared to 3 hours TCP levels were significantly decreased by 69% and 88%
after 6 hours and 12 hours respectively. Interestingly, peak hepatic TCP levels at 3
hours in high fat fed animals were significantly lower compared to peak TCP levels of
standard diet fed animals at 3 hours. The overall hepatic TCP levels were significantly
decreased in high fat fed animals compared to standard diet fed animals based on AUC
measurements (Figure 21D, Table 5), which is most likely due to a significant decrease
in peak levels in obese animals at 3 hours compared to standard diet fed animals. The
recovery percentage of TCP with the proposed UPLC method in the liver was 77% and
was 72% in plasma (Table 6).
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Measurement of TCP levels in the liver and plasma.

Plasma (A) and hepatic (B) TCP levels were determined, and AUC values were
determined for the overall availability of TCP in plasma (C) and the liver (D). Data
represent the mean ± SEM of n = 5-6 animals/group. *P≤0.05 vs. 3 hours STD or STD
(AUC). &P≤0.05 vs. 3 hours HFD, %P≤0.05 vs. 6 hours STD, #P≤0.05 to the
corresponding STD time point.
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Table 4.2

AUC of CPS and TCP in plasma and liver

Overall CPS and TCP levels in plasma and the liver over the time points were
calculated. *P≤0.05 vs. STD Liver TCP AUC.

Table 4.3

Recovery percentage of CPS and TCP in plasma and liver

Recovery percent of CPS and TCP in plasma and the liver tissue, samples from nonexposed animals were determined by following the experimental procedure as
explained by spiking of exogenous CPS and TCP with a range of known concentrations
(3 ng/ml - 300 ng/ml).
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4.4

Discussion
The current study was designed to determine the effect of high fat diet fed

induced obesity on the bioavailability of CPS and its detoxication metabolite, TCP. As
previously mentioned, TCP is formed from parent compound CPS by dearylation
reaction and from bioactivated product CPO by detoxication mechanisms. There are
studies examining the pharmacokinetics and pharmacodynamics of acute CPS
exposure in normal animals and well established physiologically based pharmacokinetic
(PBPK) models based on the studies in normal rodents and human volunteers (Nolan et
al., 1984; Timchalk, 2010; Timchalk et al., 2002). Pharmacodynamic studies in animal
models (rats) and humans have been previously reported examining inhibition of ChE
activities following acute exposures to CPS, but there are no studies examining the
effects of high fat diet induced obesity on CPS accumulation and biotransformation to its
major metabolite, TCP (Suemizu et al., 2014; Timchalk, 2010).
Previous studies in normal CD-1 mice demonstrated acute exposure to CPS (25
mg/kg via oral dose) produced approximately 20% inhibition of AChE activity in the
brain after 3 hours (Cometa et al., 2007). The current study results also indicate CNS
AChE activity was slightly inhibited following exposure to CPS (25 mg/kg) by 10% - 20%
after 3 hours to 12 hours in high fat diet and standard diet animals. However, this
inhibition was not statistically significant compared to vehicle treated animals at the 0
hour time point. Exposure to CPS (25 mg/kg) in CD-1 mice inhibited serum ChE activity
by 75% up to 72 hours compared to control animals (Cometa et al., 2007). In the current
study, exposure to CPS (25 mg/kg) significantly decreased serum ChE activity by ~70%
and ~90% after 3 hours in high fat fed animals and standard diet fed animals,
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respectively. The sensitivities of cholinesterase activities following CPS (25 mg/kg)
exposure and in the current study are plasma > RBC > brain, which is comparable to
previously reported PB/PK model in rats. In these rat studies, the degree of
experimentally determined cholinesterase inhibition was generally dose-dependent and
the relative sensitivities to inhibition were plasma > RBC ≥ brain (Timchalk et al., 2005).
PON-1 primarily functions as a protective mechanism against OP toxicity. PON-1
is a plasma enzyme associated with HDL and a detoxication mechanism involved in the
metabolism of OP-oxon metabolites, including CPO by hydrolysis (Costa et al., 1999).
In addition, PON-1 has a protective role in the atherosclerotic process by contributing to
the HDL protective role by preventing LDL oxidation (Furlong et al., 2010). Low PON-1
activity is associated with increased CPO sensitivity (Lacasaña et al., 2010). In the
current study, following CPS exposure there was no significant effect detected on
plasma PON-1 activity in high fat diet animals but there was a significant decrease in
plasma PON-1 activity in standard diet animals. However, when the basal PON-1
activity in high fat diet animals was compared to basal PON-1 activity in standard diet
animals there was no significant differences in activities. Given PON-1 is known to act
as a detoxication mechanism, the decrease in PON-1 activity in standard diet animals
indicate that PON-1 may be protecting from CPO.
The OP pesticides, including CPS, have the ability to inhibit noncholinergic
targets of OP toxicity, including CES, FAAH, and MAGL (Casida et al., 2005). A single
or repeated administration of CPS (2 mg/kg) produced increased inhibition of CES
activity in the liver (Howell et al., 2018). Plasma CES activity was inhibited in both
standard and high fat diet fed animals but significantly recovered after 12 hours in high
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fat diet animals with the current CPS (25 mg/kg) exposure. CES plays an important role
in the detoxication of xenobiotics, including CPO, and lipid mobilization from the liver.
Thus, inhibition of CES may impact the detoxication of CPS or alter lipid metabolism
(Ross et al., 2014). As in our previous study (Chapter 3), using CPS (2 mg/kg), the
administration of a higher dose of CPS (25 mg/kg) did not significantly inhibit hepatic
MAGL activity from 3-12 hours in standard diet or high fat fed animals. Our previous
study (Chapter 3) with CPS (2 mg/kg) produced significant inhibition of hepatic FAAH
activity (35% inhibition) in obese animals after 12 hours. This inhibition was increased in
the present study by exposure to the higher dosage of CPS (25 mg/kg) which inhibited
hepatic FAAH activity by 44% - 52% after 12 hours in the standard diet and high fat diet
fed animals, respectively. The present CES and FAAH activities were more sensitive
than MAGL following acute CPS (25 mg/kg) administration, which are in agreement with
previously reported sensitivities of these noncholinergic OP target enzymes towards
CPO as well as the results in Chapter 3 using a lower dose of CPS (2 mg/kg) (Casida et
al., 2005; Quistad et al., 2006).
CPS administered in corn oil appears to be well absorbed (around 80%) over a
range of dose levels (Ahdaya et al., 1981; Timchalk et al., 2002). Exposure to CPS (10
mg/kg) in TK-NOG mice inhibited plasma butyrylcholinesterase (BChE) activity by 2 fold
with peak inhibition observed after 0.5 hours and exposure to CPS (30 mg/kg) produced
peak plasma levels of CPS after 2 - 4 hours. Detectable CPS levels were found up to 7
hours after dosing (Suemizu et al., 2018; Suemizu et al., 2014). The current dosage in
this study is considered a high dose and utilized to quantitatively measure the CPS and
TCP levels. Environmentally relevant CPS exposures in humans are usually at low
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levels and the high doses have only occurred with accidental or intentional exposures.
At low levels, plasma accumulation of CPS may not be detectable due to its quick
conversion to CPO and TCP. The biological half-life of CPS in blood was estimated to
be 8 hours following acute intravenous administration (CPS 70 mg/kg) in rodents
(Sunaga et al., 1989). The biological half-life of radiolabeled CPS following oral
administration was estimated to be 10 hours and 62 hours in liver and fat, respectively,
in normal rats (Smith et al., 1967). The prolonged half-life in fat is possibly due to the
lipophilic properties of CPS. In rats, CPS primarily accumulates in the adipose tissue
compared to other tissue compartments following oral administration (Bakke et al.,
1976). The tissue: blood partition coefficients (log p) values for CPS were estimated in
the liver (22:1) and fat (435:1) tissue (Timchalk et al., 2002). Due to its high lipophilicity
and the prolonged half-life of CPS in fat, CPS levels were expected to be increased
over time in the liver (due to steatosis). While the liver levels were greater than the
plasma levels in the current study, peak CPS levels in plasma and liver were observed
after 3 hours in both the standard diet and high fat diet fed animals. Therefore, high fat
diet induced obesity did not appear to affect the overall CPS levels in these two depots
at the currently utilized time points.
CPS can be metabolized to TCP by different routes. Initially, CPS will be
bioactivated to CPO which will inhibit the OP target serine hydrolases including AChE,
BChE, CES, FAAH, and MAGL, or CPS will be deactivated by dearylation to TCP. CPS
itself can also be directly detoxified by CYP450 isozymes to form TCP. TCP is the major
metabolite formed from the metabolism of CPS or CPO and TCP is less lipophilic and is
more stable than its parent compound CPS and toxic metabolite CPO. TCP is cleared
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from the body by the kidneys through urinary excretion (Sultatos et al., 1984). Previous
studies in mice given CPS (30 mg/kg) via oral gavage reveal that the liver contributes to
the elimination of CPS by the formation of 77% of TCP metabolite (Suemizu et al.,
2014). The current study showed a significant decrease in hepatic TCP levels after 3
hours in high fat-fed animals compared to the standard diet fed animals. The peak
plasma TCP levels were observed after 3 hours in obese animals and after 6 hours in
standard diet animals. The possibility arises that increased lipid accumulation in the liver
following high fat diet intake in addition to the greater water solubility of TCP compared
to its parent compound CPS may increase the clearance of TCP from the liver due to fat
accumulation. A recognized limitation of this study is that it does not address the time
points before 3 hours to determine if peak levels of CPS and TCP occurred prior to 3
hours and that it does not follow these levels past 12 hours.
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4.5

Conclusion
In summary, our current study indicates hepatic CES and FAAH activities are

more sensitive than MAGL towards the current dose of CPS (25 mg/kg) in the standard
diet and high fat diet fed animals, which is comparable to CPS (2 mg/kg). Plasma PON1 activity was not altered in CPS exposed high fat fed animals with the current dose of
CPS exposure when compared to CPS exposed standard diet fed animals. The
bioavailability of parent compound CPS did not appear to be altered in the liver and
plasma of the high fat diet fed animals, but the clearance of the detoxified metabolite
TCP in the liver did appear to be altered. Obesity might be an important risk factor for
the toxicokinetics by altering the detoxication of the parent compound and
toxicodynamics by altering CPS mediated inhibition of specific serine hydrolase
enzymes.
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CHAPTER V
CONCLUSION

Organophosphates (OPs), including chlorpyrifos (CPS), have been widely used
as insecticides in agriculture and household settings. Several studies have
demonstrated that exposures to OP pesticides lead to metabolic abnormalities including
dyslipidemia, which is often associated with obesity and nonalcoholic fatty liver disease
(NAFLD) (Howell et al., 2016; Slotkin et al., 2005). The primary mechanism of acute
neurotoxic action of CPS is through the inhibition of the acetylcholinesterase (AChE) in
the central and peripheral nervous systems. Along with AChE inhibition, secondary
targets of OPs are other serine hydrolase enzymes consisting mainly of
carboxylesterases (CES), monoacylglycerol lipase (MAGL), and fatty acid amide
hydrolase (FAAH). These secondary targets are inhibited at lower levels of CPS
exposure, where this is no central nervous system (CNS) AChE inhibition (Carr et al.,
2011; Howell et al., 2018; Quistad et al., 2006). Biologically, these serine hydrolase
enzymes play important roles in physiological processes including lipid metabolism,
immune responses, and neurotransmission. OPs, including CPS, are considered
lipophilic compounds and tissue distribution varies with lipid content. OPs like CPS can
be readily stored in fat, may bioaccumulate, and then slowly released over time with an
increase in CPS toxicity (Chambers et al., 1993). Given the possibility of CPS toxicity
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being altered by lipid accumulation, the primary goal of the study was to determine if
steatotic or obese conditions may alter CPS mediated toxicity at cholinergic and
noncholinergic endpoints. The effects of CPS exposure on cholinergic and
noncholinergic endpoints observed in this study are shown in the schematic (Figure 22).

Figure 5.1

Schematic representation of the effects of CPS exposure on
inhibition/alteration of enzyme activities in normal and high fat conditions.

Our in vitro studies were performed to determine alterations in the noncholinergic
targets of OPs in the liver following CPS exposure. These studies indicated selective
potency following CPS exposure in hepatocytes, with CES and FAAH activities being
more sensitive to inhibition than MAGL activities in both MCA cells and primary
hepatocytes. The CES activity is more sensitive to CPS mediated inhibition in steatotic
MCA cells than in normal MCA cells. Exposure to CPS in MCA cells significantly
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increases neutral lipid accumulation and this may partially be due to the CPS mediated
inhibition of these target serine hydrolases including CES and FAAH which are also
involved in hepatic lipid metabolism. (Howell et al., 2016). The current in vitro data
indicates that the presence of steatotic conditions increases inhibition of hepatic CES
activity following CPS exposure (Figure 22). However, it is not known if this in vitro
phenomenon can be extrapolated to an in vivo model. Thus, the currently observed
effects of CPS on noncholinergic endpoints in hepatocytes were explored in a whole
animal model of obesity to provide more physiological relevance with altered lipid
metabolism.
Based on the results from in vitro study, the second part of the study focused on
determining the effects of how high fat diet induced obesity may alter CPS mediated
toxicity as indicated by cholinergic and noncholinergic endpoints. Our current in vivo
studies also demonstrated that CPS mediated inhibition of hepatic CES and FAAH was
more sensitive than the MAGL (Figure 22). Exposure to CPS (2 mg/kg) also produced
increased inhibition of CES and FAAH in high fat diet fed animals compared to standard
diet fed animals. A recognized limitation of the lower dose CPS (2 mg/kg) study is that it
does not address time-dependent changes in CPS mediated enzyme inhibition, such as
examining whether hepatic steatosis alters the time course of CPS-mediated inhibition
of CES and FAAH. The serine hydrolase activities constituting a difference in inhibition
following exposure to CPS might be due to the steatotic state of livers following high fat
feeding. Our in vitro results also indicate that inhibition of CES activity is more
pronounced in steatotic hepatocytes than normal hepatocytes. CPS is a highly lipophilic
compound, and it can accumulate in fat and proposed the hypothesis that prolonged
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CPS effects may persist due to the formation of storage depots in lipid rich tissues that
occur in obesity.
Based on the in vitro and in vivo results the CPS may accumulate in fat due to
steatotic conditions and leach overtime to produce more pronounced effects following
CPS exposure. Lastly, we examined the toxicokinetics and toxicodynamics of CPS
exposure. The goal of the study was to characterize the potential differences for
observed interactions between high fat diet and CPS exposure. This characterization
helped to answer the question regarding the possible potentiation of CPS mediated
inhibition of these serine hydrolases, and on the bioavailability of the parent compound
(CPS) or its detoxified metabolite 3,5,6- trichloro-2-pyridinol (TCP). We utilized CPS (25
mg/kg) to perform a metabolic analysis of the parent compound and its major detoxified
metabolite TCP. CPS levels in plasma and the liver tissue assessed were closer to the
limit of detection levels at 12 hour time points with the current CPS (25 mg/kg) dose.
High fat diet intake did not significantly alter the CPS levels in the liver and plasma, but
the overall hepatic TCP levels were decreased in high fat diet animals when compared
to standard diet animals (Figure 22). Thus, this indicates that high fat diet induced
obesity does not significantly alter CPS bioaccumulation. However, adipose levels of
CPS need to be explored to truly determine if a depot is being formed.

5.2

Future directions
Future studies should be conducted using in vivo conditions to fully characterize

the effect on the cholinergic and noncholinergic targets following chronic CPS
exposures at low doses comparable to environmental exposure levels. These studies
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should include an experimental design that will determine whether the degree of obesity
and type 2 diabetes progression exacerbates CPS exposure mediated cholinergic and
noncholinergic toxicity. Both in vitro and in vivo studies should be conducted to
determine the specific isoforms of hepatic CES that are inhibited following CPS
exposure using specific inhibitors. In vivo studies should be conducted using more
prolonged time points to determine the levels of the parent compound and the major
detoxified metabolite TCP following acute CPS exposures to develop more in-depth
physiologically based pharmacokinetic (PBPK) models and/or pharmacodynamic
models. The future studies should be conducted on the effect of a high fat diet on CPS
exposure mediating PON-1 activity in the liver to determine the gene expression of
PON-1 polymorphisms and the measurement of the PON-1 activity in the liver.
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